<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title>International Journal of Molecular Sciences</journal-title>
<abbrev-journal-title>Int. J. Mol. Sci.</abbrev-journal-title>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>Molecular Diversity Preservation International (MDPI)</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3390/ijms11072715</article-id>
<article-id pub-id-type="publisher-id">ijms-11-02715</article-id>
<article-categories>
<subj-group>
<subject>Review</subject></subj-group></article-categories>
<title-group>
<article-title>Nitric Oxide: Perspectives and Emerging Studies of a Well Known Cytotoxin</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Paradise</surname><given-names>William A.</given-names></name><xref ref-type="aff" rid="af1-ijms-11-02715">1</xref><xref ref-type="aff" rid="af2-ijms-11-02715">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>Vesper</surname><given-names>Benjamin J.</given-names></name><xref ref-type="aff" rid="af1-ijms-11-02715">1</xref><xref ref-type="aff" rid="af2-ijms-11-02715">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>Goel</surname><given-names>Ajay</given-names></name><xref ref-type="aff" rid="af3-ijms-11-02715">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>Waltonen</surname><given-names>Joshua D.</given-names></name><xref ref-type="aff" rid="af4-ijms-11-02715">4</xref></contrib>
<contrib contrib-type="author">
<name><surname>Altman</surname><given-names>Kenneth W.</given-names></name><xref ref-type="aff" rid="af5-ijms-11-02715">5</xref></contrib>
<contrib contrib-type="author">
<name><surname>Haines</surname><given-names>G. Kenneth</given-names><suffix>III</suffix></name><xref ref-type="aff" rid="af6-ijms-11-02715">6</xref></contrib>
<contrib contrib-type="author">
<name><surname>Radosevich</surname><given-names>James A.</given-names></name><xref ref-type="aff" rid="af1-ijms-11-02715">1</xref><xref ref-type="aff" rid="af2-ijms-11-02715">2</xref><xref ref-type="corresp" rid="c1-ijms-11-02715">*</xref></contrib></contrib-group>
<aff id="af1-ijms-11-02715">
<label>1</label> Center for Molecular Biology of Oral Diseases, College of Dentistry, University of Illinois at Chicago, Chicago, IL 60612, USA; E-Mails: <email>paradise@uic.edu</email> (W.A.P.); <email>vesperbe@uic.edu</email> (B.J.V.)</aff>
<aff id="af2-ijms-11-02715">
<label>2</label> Department of Jesse Brown, Veterans Administration Medical Center, Chicago, IL 60612, USA</aff>
<aff id="af3-ijms-11-02715">
<label>3</label> Division of Gastroenterology, Department of Internal Medicine, Charles A. Sammons Cancer Center and Baylor Research Institute, Baylor University Medical Center, Dallas, TX 75246, USA; E-Mail: <email>ajay.goel@baylorhealth.edu</email></aff>
<aff id="af4-ijms-11-02715">
<label>4</label> Department of Otolaryngology, Wake Forest University, Winston-Salem, NC 27157, USA; E-Mail: <email>jwaltone@wfubmc.edu</email></aff>
<aff id="af5-ijms-11-02715">
<label>5</label> Mount Sinai School of Medicine, New York, NY 10029, USA; E-Mail: <email>Kenneth.altman@mountsinai.org</email></aff>
<aff id="af6-ijms-11-02715">
<label>6</label> Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA; E-Mail: <email>k.haines@yale.edu</email></aff>
<author-notes>
<corresp id="c1-ijms-11-02715">
<label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>jrados@uic.edu</email>.</corresp></author-notes>
<pub-date pub-type="collection">
<year>2010</year></pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>7</month>
<year>2010</year></pub-date>
<volume>11</volume>
<issue>7</issue>
<fpage>2715</fpage>
<lpage>2745</lpage>
<history>
<date date-type="received">
<day>26</day>
<month>5</month>
<year>2010</year></date>
<date date-type="rev-recd">
<day>17</day>
<month>6</month>
<year>2010</year></date>
<date date-type="accepted">
<day>13</day>
<month>7</month>
<year>2010</year></date></history>
<permissions>
<copyright-statement>© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.</copyright-statement>
<copyright-year>2010</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p></license></permissions>
<abstract>
<p>The free radical nitric oxide (NO<sup>•</sup>) is known to play a dual role in human physiology and pathophysiology. At low levels, NO<sup>•</sup> can protect cells; however, at higher levels, NO<sup>•</sup> is a known cytotoxin, having been implicated in tumor angiogenesis and progression. While the majority of research devoted to understanding the role of NO<sup>•</sup> in cancer has to date been tissue-specific, we herein review underlying commonalities of NO<sup>•</sup> which may well exist among tumors arising from a variety of different sites. We also discuss the role of NO<sup>•</sup> in human physiology and pathophysiology, including the very important relationship between NO<sup>•</sup> and the glutathione-transferases, a class of protective enzymes involved in cellular protection. The emerging role of NO<sup>•</sup> in three main areas of epigenetics—DNA methylation, microRNAs, and histone modifications—is then discussed. Finally, we describe the recent development of a model cell line system in which human tumor cell lines were adapted to high NO<sup>•</sup> (HNO) levels. We anticipate that these HNO cell lines will serve as a useful tool in the ongoing efforts to better understand the role of NO<sup>•</sup> in cancer.</p></abstract>
<kwd-group>
<kwd>nitric oxide</kwd>
<kwd>epigenetics</kwd>
<kwd>cytotoxicity</kwd>
<kwd>high NO adaptation</kwd>
<kwd>oncogenetic</kwd></kwd-group></article-meta></front>
<body>
<sec>
<label>1.</label>
<title>Background</title>
<p>NO<sup>•</sup> is a free radical which was discovered in 1980 as a ubiquitous diffusible second messenger. While some authors use the term “nitric oxide” to refer to any of the nitric oxide reactive species (NO<sup>•</sup>, NO<sup>−</sup>, and NO<sup>+</sup>), in biological settings, nitric oxide usually refers to the free radical. NO<sup>•</sup> was determined to be a prominent constituent of what was then called endothelium-derived relaxing factor (EDRF) [<xref ref-type="bibr" rid="b1-ijms-11-02715">1</xref>]. Later in 1985, <italic>Eschericia coli</italic> lipopolysacchride (LPS) was found to initiate production of NO<sup>•</sup> by LPS-stimulated mouse macrophages [<xref ref-type="bibr" rid="b2-ijms-11-02715">2</xref>]. We now know the molecule plays a significant role in both normal and abnormal physiology of human beings, as well as plants and invertebrates [<xref ref-type="bibr" rid="b3-ijms-11-02715">3</xref>–<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>]. NO<sup>•</sup> has a well characterized two-step synthetic metabolic pathway in which <italic>L</italic>-arginine is first converted to <italic>N</italic><sub>G</sub>-hydroxy-<italic>L</italic>-arginine and then to <italic>L</italic>-citrulline and NO<sup>•</sup>. This reaction is catalyzed by the enzymatic family of nitric oxide synthases (NOSs). Three NOS isoforms exist: 1) nNOS/NOS1, a calcium-dependent enzyme discovered in neurons that is involved in neural transmission; 2) iNOS/NOS2, a calcium-independent enzyme that releases large amounts of NO<sup>•</sup> in response to macrophage activation with endotoxin and cytokines, and is involved in cytotoxicity; and 3) eNOS/NOS3, also a calcium-dependent enzyme that is constitutively expressed, isolated from endothelial cells, and is found in normal vascular endothelium [<xref ref-type="bibr" rid="b6-ijms-11-02715">6</xref>,<xref ref-type="bibr" rid="b7-ijms-11-02715">7</xref>]. Once NO<sup>•</sup> is produced, it can react with various molecules, resulting in more stable compounds such as S-nitrosothiols, metal adducts, peroxynitrites (while in the presence of oxygen), and tetrahydrobiopterin (THB) [<xref ref-type="bibr" rid="b6-ijms-11-02715">6</xref>]. THB is recognized as a necessary prerequisite for the biosynthesis of key aromatic amino acid hydroxylase enzyme precursors necessary for synthesis of neurotransmitters such as serotonin, melatonin, epinephrine and dopamine.</p>
<p>It is believed NO<sup>•</sup> regulates the physiology and pathophysiology of the body through one of three biomolecular mechanisms: 1) redox interactions with thiols, 2) coordinating interactions with metal functional centers, and 3) through protein kinase activity [<xref ref-type="bibr" rid="b8-ijms-11-02715">8</xref>]. The role and impact of NO<sup>•</sup> is believed to be widespread because of its ability to cross cell membranes in an unaltered chemical form, diffuse rapidly, interact with key generative and target cell-response proteins, and quickly interact with key transition metal containing proteins [<xref ref-type="bibr" rid="b6-ijms-11-02715">6</xref>].</p>
<p>The various biomolecular mechanisms of NO<sup>•</sup> result in numerous biological functions, including: 1) antitumor and microbial immunity, including against gram positive organisms [<xref ref-type="bibr" rid="b6-ijms-11-02715">6</xref>], 2) immuno-modulation and allo-antigenicity [<xref ref-type="bibr" rid="b9-ijms-11-02715">9</xref>,<xref ref-type="bibr" rid="b10-ijms-11-02715">10</xref>], and 3) a signaling pathway [<xref ref-type="bibr" rid="b6-ijms-11-02715">6</xref>]. Nearly every cell throughout the body has the ability to express calcium-independent iNOS [<xref ref-type="bibr" rid="b6-ijms-11-02715">6</xref>]. Within the central nervous system, learning, sleep, feeding, male and female reproductive behavior are all impacted by NO<sup>•</sup> [<xref ref-type="bibr" rid="b11-ijms-11-02715">11</xref>]. It also influences the neurotransmitters in synapses between peripheral organs [<xref ref-type="bibr" rid="b11-ijms-11-02715">11</xref>] and regulates angiogenesis and neurogenesis after stroke activity [<xref ref-type="bibr" rid="b12-ijms-11-02715">12</xref>]. NO<sup>•</sup> also delays the aging of oocytes [<xref ref-type="bibr" rid="b13-ijms-11-02715">13</xref>], controls resting potential in skeletal muscle [<xref ref-type="bibr" rid="b14-ijms-11-02715">14</xref>], regulates contraction-excitation coupling [<xref ref-type="bibr" rid="b14-ijms-11-02715">14</xref>], and modulates chondrocyte development during endochondral ossification [<xref ref-type="bibr" rid="b15-ijms-11-02715">15</xref>]. Significantly, NO<sup>•</sup> depravation is a critical underlying cause for endothelial dysfunction, which in turn is a key common contributor to diabetes-related cardiovascular disease, myocardial infarction, and atherosclerosis [<xref ref-type="bibr" rid="b16-ijms-11-02715">16</xref>,<xref ref-type="bibr" rid="b17-ijms-11-02715">17</xref>].</p>
<p>NO<sup>•</sup> in low concentrations is now known to have benign, modulating, and regulatory effects on normal mammalian and human biology and physiology. Higher concentration levels of NO<sup>•</sup> are now shown to be both damaging and pathologic to physiologic processes [<xref ref-type="bibr" rid="b6-ijms-11-02715">6</xref>]. What is defined as a high or low level can vary enormously depending upon which physiologic system the free radical is found and the apparent contradictory functional impact of NO<sup>•</sup> presence on a particular molecular mechanism and biochemical microenvironment [<xref ref-type="bibr" rid="b6-ijms-11-02715">6</xref>]. For instance, at NO<sup>•</sup> concentrations of less than 100 nM, cyclic guanosine monophosphate (cGMP), cGMP-dependent protein kinase (PKG) and extracellular signal regulated kinase (ERK) activation can occur. As concentration levels increase Akt is phosphorylated, and in ranges between 300 to 800 nM hypoxia inducible factor-1 alpha and p53 are stabilized [<xref ref-type="bibr" rid="b18-ijms-11-02715">18</xref>]. As concentrations increase further, nitrosation and oxidative processes become prominent and initiate stressful cellular events [<xref ref-type="bibr" rid="b19-ijms-11-02715">19</xref>]. However, the role of NO<sup>•</sup> can be either protective or toxic, depending upon the unique biochemical content of the microenvironment in which it exists [<xref ref-type="bibr" rid="b20-ijms-11-02715">20</xref>].</p>
<p>It is also now well established that NO<sup>•</sup> plays a multifaceted and contradictory role in the biology and growth of tumors [<xref ref-type="bibr" rid="b21-ijms-11-02715">21</xref>]. Over-expression of NOS has been shown to be responsible for tumor angiogenesis and maintaining vascular tone within tumor blood vessel systems [<xref ref-type="bibr" rid="b22-ijms-11-02715">22</xref>–<xref ref-type="bibr" rid="b25-ijms-11-02715">25</xref>], as well as the facilitation of neoplastic transformation [<xref ref-type="bibr" rid="b22-ijms-11-02715">22</xref>,<xref ref-type="bibr" rid="b26-ijms-11-02715">26</xref>,<xref ref-type="bibr" rid="b27-ijms-11-02715">27</xref>]. Studies have shown that in cancer patients, NO<sup>•</sup> regulates blood flow to tumors, and by down-regulating NO<sup>•</sup> synthesis, a distinct vasoconstricting event results [<xref ref-type="bibr" rid="b22-ijms-11-02715">22</xref>]. This has been demonstrated through the use of <italic>N</italic>-nitro-<italic>L</italic>-arginine (<italic>L</italic>-NNA) to reduce blood flow to tumors in BD9 rats with P22 carcinosarcoma [<xref ref-type="bibr" rid="b22-ijms-11-02715">22</xref>,<xref ref-type="bibr" rid="b28-ijms-11-02715">28</xref>]. In humans cancer patients reducing NOS results in an increase in blood pressure [<xref ref-type="bibr" rid="b22-ijms-11-02715">22</xref>,<xref ref-type="bibr" rid="b29-ijms-11-02715">29</xref>,<xref ref-type="bibr" rid="b30-ijms-11-02715">30</xref>]. At higher concentrations in the proper microenvironment, for an extended period of time, NO<sup>•</sup> exposure initiates inflammation, can stimulate tumor growth and/or metastatic behavior [<xref ref-type="bibr" rid="b6-ijms-11-02715">6</xref>,<xref ref-type="bibr" rid="b7-ijms-11-02715">7</xref>], and can lead to mutations and the clinical presentation of cancer [<xref ref-type="bibr" rid="b9-ijms-11-02715">9</xref>,<xref ref-type="bibr" rid="b31-ijms-11-02715">31</xref>,<xref ref-type="bibr" rid="b32-ijms-11-02715">32</xref>]. Exogenous sources of NO<sup>•</sup>, such as cigarette smoke, contribute to subcellular damage through the formation of <italic>N</italic>-nitrosoamines and N-nitrosamides, contributing to elevated expression of head and neck cancers [<xref ref-type="bibr" rid="b7-ijms-11-02715">7</xref>,<xref ref-type="bibr" rid="b33-ijms-11-02715">33</xref>–<xref ref-type="bibr" rid="b36-ijms-11-02715">36</xref>].</p>
<p>It is also well recognized that reactive oxygen species (ROSs) play an important function in either the protective or pathologic expression of NO<sup>•</sup> reactions with oxygen [<xref ref-type="bibr" rid="b6-ijms-11-02715">6</xref>,<xref ref-type="bibr" rid="b7-ijms-11-02715">7</xref>]. ROSs provide beneficial impacts through killing of microorganisms and malignant cells, or a pathologic effect, again depending upon the microenvironment. Higher concentrations of ROS generate oxidative and nitrosative environmental stressors leading to: 1) DNA damage, 2) down-regulated antioxidants, and 3) an impact on transcription/translation activities, thereby generally impairing normal cellular function [<xref ref-type="bibr" rid="b7-ijms-11-02715">7</xref>,<xref ref-type="bibr" rid="b37-ijms-11-02715">37</xref>,<xref ref-type="bibr" rid="b38-ijms-11-02715">38</xref>]. Should DNA become damaged from either endogenous or exogenous sources of NO<sup>•</sup>, a number of defensive apoptotic systems are initiated to protect against unwanted cellular transformation [<xref ref-type="bibr" rid="b6-ijms-11-02715">6</xref>,<xref ref-type="bibr" rid="b7-ijms-11-02715">7</xref>]. Amongst the most important defensive apoptotic systems is the up regulation of DNA damage sensing proteins, such as p53. Damage not repaired typically results in cellular death through apoptosis. NO<sup>•</sup> is also known to inhibit caspase activation, which in turn is known to induce normal apoptosis. Studies have also shown NO<sup>•</sup> prohibits apoptosis in a variety of cell types, as well as in some tumor cells [<xref ref-type="bibr" rid="b39-ijms-11-02715">39</xref>,<xref ref-type="bibr" rid="b40-ijms-11-02715">40</xref>].</p></sec>
<sec>
<label>2.</label>
<title>GST-pi</title>
<p>Thiols are a group of biological molecules which act as intracellular antioxidants. Among the most studied forms is glutathione (GSH), known to react with and neutralize electrophilic centers of a number of environmental and oxidative cellular stressors. The enzyme which catalyzes these reactions is glutathione S-transferase-pi (GST-pi), one of a family of Phase II detoxifying glutathione S-transferases (GSTs) responsible not only for detoxification, but also activation of significant biochemical pathways essential to normal physiology [<xref ref-type="bibr" rid="b41-ijms-11-02715">41</xref>]. These oxidative stressors include elevated levels of NO<sup>•</sup>. The GST isoenzymes and their behavior are essential to providing yet another tool toward protection of DNA from a variety of endogenous and exogenous pathogenic sources [<xref ref-type="bibr" rid="b42-ijms-11-02715">42</xref>–<xref ref-type="bibr" rid="b44-ijms-11-02715">44</xref>]. Equally important, the GSTs catalyze the conjugation of GSH to an array of xenobiotic or toxic compounds rendering them non-toxic [<xref ref-type="bibr" rid="b45-ijms-11-02715">45</xref>]. Due to these behaviors GSTs are an important area of research in molecular biology.</p>
<p>While GST isoenzymes relieve the source of toxicity, the catalytic group is also strongly implicated in the development of cellular resistance to anti-cancer drug therapy [<xref ref-type="bibr" rid="b42-ijms-11-02715">42</xref>,<xref ref-type="bibr" rid="b45-ijms-11-02715">45</xref>]. It provides a mechanism to explain cancer patients’ observed resistance to anticancer drug therapies [<xref ref-type="bibr" rid="b45-ijms-11-02715">45</xref>]. Tumor cell lines which over-express GST-pi have heightened detoxification responses and acquire increased resistance to compounds perceived by the body as being toxic, including chemotherapeutic drugs [<xref ref-type="bibr" rid="b42-ijms-11-02715">42</xref>,<xref ref-type="bibr" rid="b45-ijms-11-02715">45</xref>,<xref ref-type="bibr" rid="b46-ijms-11-02715">46</xref>]. GST isoenzymes are categorized into three primary groups: 1) cytosolic, 2) membrane-bound microsomal, and 3) mitochondrial [<xref ref-type="bibr" rid="b45-ijms-11-02715">45</xref>]. The cytosolic type is further divided into seven classes: 1) Alpha, 2) Mu, 3) Omega, 4) Pi, 5) Sigma, 6) Theta, and 7) Zeta [<xref ref-type="bibr" rid="b45-ijms-11-02715">45</xref>]. GST-pi is now recognized to be the predominant isoform subclass [<xref ref-type="bibr" rid="b42-ijms-11-02715">42</xref>,<xref ref-type="bibr" rid="b44-ijms-11-02715">44</xref>].</p>
<p>The GST-pi gene has four functional polymorphisms (GSTP1*A, GSTP1*B, GSTP1*C, and GSTP1*D), with each allelic genotype having different treatment response outcomes among individual cancer patients [<xref ref-type="bibr" rid="b45-ijms-11-02715">45</xref>,<xref ref-type="bibr" rid="b47-ijms-11-02715">47</xref>]. Examples include: 1) GSTP1*A is responsible for acquired resistance to cisplatin treatment due to creation of platinum-GSH conjugates [<xref ref-type="bibr" rid="b48-ijms-11-02715">48</xref>], 2) GSTP1*B, which in certain circumstances, is associated with an impaired ability to detoxify platinum based therapeutic treatment [<xref ref-type="bibr" rid="b49-ijms-11-02715">49</xref>], and 3) patients testing positive for GSTP1*C appear to experience breast cancer with less frequency [<xref ref-type="bibr" rid="b50-ijms-11-02715">50</xref>]. All polymorphisms have been shown to impact, to varying degrees: 1) anticancer therapy treatment, 2) chemotherapeutic response, and 3) susceptibility to cancer. Most importantly, GSTP1 has been reported to be over-expressed in a number of different tumor types including: colon, lymphoma, pancreas, breast, NSCLC and ovarian [<xref ref-type="bibr" rid="b42-ijms-11-02715">42</xref>,<xref ref-type="bibr" rid="b51-ijms-11-02715">51</xref>]. One effort analyzed GST enzymes, GST composition, and GSH concentration levels in normal and squamous cell carcinoma tissues among 25 patients (14 with oropharyngeal or oral tumors, 11 with laryngeal tumors) [<xref ref-type="bibr" rid="b44-ijms-11-02715">44</xref>]. GST-pi levels increased in 11 of the 14 oral cavity tumors, and elevated expression of GST-pi was found in all laryngeal tumors [<xref ref-type="bibr" rid="b44-ijms-11-02715">44</xref>]. Another report provides evidence for heighten risk of relapse for laryngeal cancer associated with GST-pi over-expression [<xref ref-type="bibr" rid="b52-ijms-11-02715">52</xref>]. Others propose the possibility that up-regulated GST-pi, GST-mu, and GST-alpha can be predictors of a second primary tumor in head and neck cancers [<xref ref-type="bibr" rid="b53-ijms-11-02715">53</xref>]. Additional studies demonstrate over-expression of GST-pi within normal mucosa adjacent to tumors, dysplastic mucosal lesions, and head &amp; neck squamous cell carcinoma (HNSCC) [<xref ref-type="bibr" rid="b54-ijms-11-02715">54</xref>,<xref ref-type="bibr" rid="b55-ijms-11-02715">55</xref>]. GST-pi expression increases through a step-wise progression, correlating with up-regulated NOS and molecular markers of oxidative injury [<xref ref-type="bibr" rid="b54-ijms-11-02715">54</xref>,<xref ref-type="bibr" rid="b55-ijms-11-02715">55</xref>]. It has been hypothesized that GST-pi is over-expressed in mucosal cells in response to oxidative injury by toxins such as NO<sup>•</sup> and known nitrosative carcinogens resulting from smoking cigarettes [<xref ref-type="bibr" rid="b54-ijms-11-02715">54</xref>,<xref ref-type="bibr" rid="b55-ijms-11-02715">55</xref>].</p>
<p>Presented herein is a study in which we investigated GST-pi expression in laryngeal tumors (<xref ref-type="table" rid="t1-ijms-11-02715">Table 1</xref>). Patient charts were reviewed for TNM stage and course of treatment. Tissue sections were reviewed, and the intensity of tumor staining was graded on an immunohistochemical scale (0–4).</p>
<p>In ten patients, seven had previously undergone radiation therapy; five of the seven patients were concurrently treated with chemotherapy and radiation therapy. All patients failed treatment or had recurrence or persistent disease. The seven patients who received radiation exhibited higher levels of GST-pi expression than the three patients who were not treated with radiation. <xref ref-type="fig" rid="f1-ijms-11-02715">Figure 1</xref> shows examples of GST-pi immunostaining observed in human this study.</p>
<p>To investigate the commonality among squamous cell carcinomas arising in different sites, we also investigated the NOS and GST-pi expression of cervical squamous cell carcinomas (CSCC). Presented herein are results showing expression of eNOS, iNOS, and GST-pi in a series of patients with CSCC. Patient charts were reviewed for TNM stage, tumor grade, and course of treatment. All samples were obtained prior to treatment. Tissue sections were reviewed; the intensity of tumor staining was graded on an immunohistochemical scale (0–3). <xref ref-type="table" rid="t2-ijms-11-02715">Table 2</xref> summarizes the results.</p>
<p>Both iNOS and GST-pi were highly expressed in CSCC, whereas eNOS showed only limited expression. Examples of the observed staining are shown in <xref ref-type="fig" rid="f2-ijms-11-02715">Figure 2</xref>. The eNOS expression in CSCC was in contrast to previously reported HNSCC work which showed highly expressed eNOS [<xref ref-type="bibr" rid="b56-ijms-11-02715">56</xref>,<xref ref-type="bibr" rid="b57-ijms-11-02715">57</xref>].</p>
<p>Another reported study confirms our findings that NO<sup>•</sup> is a significant contributor to cervical cancer, and suggests a link between NO<sup>•</sup> and a number of prominent risk factors associated with the onset of cervical cancer. These factors include: 1) chronic inflammation, 2) HPV infections, 3) extended use of oral contraceptives, 4) sexually transmitted diseases, and 5) smoking tobacco [<xref ref-type="bibr" rid="b58-ijms-11-02715">58</xref>]. All of these factors cause increases in NO<sup>•</sup> levels [<xref ref-type="bibr" rid="b58-ijms-11-02715">58</xref>–<xref ref-type="bibr" rid="b61-ijms-11-02715">61</xref>] and markers of NO<sup>•</sup>-mediated mutagenesis in patients with cervical intraepithelial neoplasia [<xref ref-type="bibr" rid="b58-ijms-11-02715">58</xref>,<xref ref-type="bibr" rid="b62-ijms-11-02715">62</xref>,<xref ref-type="bibr" rid="b63-ijms-11-02715">63</xref>].</p></sec>
<sec>
<label>3.</label>
<title>Reactive Nitrogen Species</title>
<p>The role of reactive nitrogen species (RNSs) has been well documented for many decades. The impact of RNSs originates in inflammatory tissues and can result in mutations in tumor suppressor genes, leading to subsequent tumor neoplastic growth [<xref ref-type="bibr" rid="b64-ijms-11-02715">64</xref>]. RNSs also cause post-translational modifications of proteins involved in fundamental cellular functions such as apoptosis, cell cycle check point, and DNA repair [<xref ref-type="bibr" rid="b65-ijms-11-02715">65</xref>]. RNSs are known to cause both oxidation and nitration reactions resulting in DNA strand breaks, mutations in DNA base pairs, and helix modifications [<xref ref-type="bibr" rid="b65-ijms-11-02715">65</xref>]. What has also become increasingly evident over time is how important the molecular composition of the microenvironment is relative to the degree of DNA alterations. The molecular composition of the microenvironment is influenced by a number of RNS factors, including: 1) biomolecular profile, 2) type, 3) concentration level, 4) accessibility, 5) bioavailability, and 6) half life [<xref ref-type="bibr" rid="b65-ijms-11-02715">65</xref>]. RNSs can evolve further into a variety of related molecules including 4-hydroxynoneal (4-HNE) and reactive aldehydes-malondialdehydes (MDA), both of which are associated with increased cancer risk in chronic inflammatory diseases [<xref ref-type="bibr" rid="b65-ijms-11-02715">65</xref>–<xref ref-type="bibr" rid="b67-ijms-11-02715">67</xref>]. Both 4-HNE and MDA are also known to cause point mutations within tumor suppressor genes [<xref ref-type="bibr" rid="b65-ijms-11-02715">65</xref>–<xref ref-type="bibr" rid="b67-ijms-11-02715">67</xref>]. Further, RNSs play a critical role as a facilitator between signal transduction receptors such as the MAPK signaling cascade. This can lead to the expression of proto-oncogenes such as c-Jun, c-Fos, and AP-1. These proto-oncogenes impact differentiation, proliferation, cellular death, and transformation [<xref ref-type="bibr" rid="b65-ijms-11-02715">65</xref>,<xref ref-type="bibr" rid="b68-ijms-11-02715">68</xref>,<xref ref-type="bibr" rid="b69-ijms-11-02715">69</xref>]. Free radical exposure is also well recognized to cause post-translational modifications which affect the functionality of key cellular proteins. For example, exposure to NO<sup>•</sup>, an abundant RNS, leads to post-translational modifications of both p53 and Rb tumor suppressor genes at critical concentration levels [<xref ref-type="bibr" rid="b65-ijms-11-02715">65</xref>,<xref ref-type="bibr" rid="b70-ijms-11-02715">70</xref>,<xref ref-type="bibr" rid="b71-ijms-11-02715">71</xref>]. Exposure to NO<sup>•</sup> also activates DNA repair and signal transduction species including DNA protein kinases [<xref ref-type="bibr" rid="b65-ijms-11-02715">65</xref>,<xref ref-type="bibr" rid="b72-ijms-11-02715">72</xref>,<xref ref-type="bibr" rid="b73-ijms-11-02715">73</xref>].</p></sec>
<sec>
<label>4.</label>
<title>Epigenetics and NO<sup>•</sup></title>
<p>In the early 1940’s C.H. Waddington first used “epigenetics” to describe the mechanisms responsible for the developmental pathway from fertilized egg to an adult [<xref ref-type="bibr" rid="b74-ijms-11-02715">74</xref>–<xref ref-type="bibr" rid="b76-ijms-11-02715">76</xref>]. Epigenetics is known to regulate primary biological functions, including, but not limited to: 1) memory function, 2) development and aging, 3) mobile elements activity, 4) genomic imprinting, 5) viral infections, 6) somatic gene therapy, 7) cloning, 8) X-inactivation, and 9) the biology of cancer [<xref ref-type="bibr" rid="b77-ijms-11-02715">77</xref>–<xref ref-type="bibr" rid="b81-ijms-11-02715">81</xref>]. The list of diseases associated with epigenetic dysregulation continues to grow as research efforts progress [<xref ref-type="bibr" rid="b77-ijms-11-02715">77</xref>–<xref ref-type="bibr" rid="b81-ijms-11-02715">81</xref>]. Over time and with the expanded knowledge base created by the efforts of many, the term has evolved to reference the heritable modifications to chromatin, which regulate gene expression, but do not change the underlying DNA sequence [<xref ref-type="bibr" rid="b75-ijms-11-02715">75</xref>,<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>,<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>]. The impact on chromatin composition can be rapid and reversible, originating from endogenous and exogenous sources and which may well modulate gene expression behavior [<xref ref-type="bibr" rid="b47-ijms-11-02715">47</xref>,<xref ref-type="bibr" rid="b74-ijms-11-02715">74</xref>,<xref ref-type="bibr" rid="b75-ijms-11-02715">75</xref>,<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>].</p>
<p>Gene expression and silencing can be carried out via a number of interrelated epigenetic mechanisms that may be modulated by NO<sup>•</sup>. These mechanisms include, but are not limited to: 1) DNA methylation [<xref ref-type="bibr" rid="b75-ijms-11-02715">75</xref>,<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>–<xref ref-type="bibr" rid="b84-ijms-11-02715">84</xref>], 2) microRNA (miRNA) [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b85-ijms-11-02715">85</xref>,<xref ref-type="bibr" rid="b86-ijms-11-02715">86</xref>], and 3) histone modifications [<xref ref-type="bibr" rid="b75-ijms-11-02715">75</xref>,<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>,<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b83-ijms-11-02715">83</xref>,<xref ref-type="bibr" rid="b85-ijms-11-02715">85</xref>,<xref ref-type="bibr" rid="b87-ijms-11-02715">87</xref>–<xref ref-type="bibr" rid="b89-ijms-11-02715">89</xref>]. The three mechanisms combine synergistically to regulate and affect epigenetic programming and reprogramming behavior [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b85-ijms-11-02715">85</xref>,<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>–<xref ref-type="bibr" rid="b97-ijms-11-02715">97</xref>]. Herein we discuss these three mechanisms and the emerging research to date as to how these may be affected by NO<sup>•</sup>. Interestingly, a recent study involving Duchenne muscular dystrophy indicated that a diminution of NO<sup>•</sup> results in global epigenetic changes, thereby implicating NO<sup>•</sup> as an “epigenetic molecule” [<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>].</p>
<sec>
<label>4.1.</label>
<title>DNA Methylation</title>
<p>Chromatin is made up of nucleosomes. The nucleosomes are comprised of DNA (146–147 base pairs in length, depending upon the literature cited [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b84-ijms-11-02715">84</xref>]) and histones. The DNA is wrapped in a left-handed super-helix 1.7 times surrounding a core complex of eight histones [<xref ref-type="bibr" rid="b84-ijms-11-02715">84</xref>], two each of H2A, H2B, H3, and H4 [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b86-ijms-11-02715">86</xref>]. Each histone within the core has two active functional regions: 1) a “histone-fold” area to facilitate histone-to-histone and histone-to-DNA interactions in nucleosomes, and 2) a NH<sub>2</sub>-terminal with COOH-terminal “tails,” which are the sites for post-translational modifications that include methylation, phosphorylation, ubiquitination, and acetylation [<xref ref-type="bibr" rid="b84-ijms-11-02715">84</xref>]. The tails also appear to facilitate linkage between other nucleosomes and/or DNA [<xref ref-type="bibr" rid="b87-ijms-11-02715">87</xref>]. Chromatin also allows DNA molecules, comprised of millions of nucleotides, hundreds of millions of base pairs in length, to be housed highly compressed within the cell nucleus [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b98-ijms-11-02715">98</xref>]. Less tightly bound chromatin usually has more reactive sites available for histone alterations, which in turn reversibly modify chromatin structure [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>].</p>
<p>The DNA methylation and chromatin reconfiguration processes have equally prominent, yet reversible roles in mediating the genome into transcriptionally expressed or unexpressed segments [<xref ref-type="bibr" rid="b77-ijms-11-02715">77</xref>,<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>]. Some patterns of DNA methylation remain constant throughout adulthood, while others are reversible. The on-going and mutable role of histones is reversible and also facilitates the silencing or unsilencing of gene expression. Tumorigenesis is a key example of pathological dysregulation in chromatin remodeling, or a lack of normalcy in DNA methylation processing behavior [<xref ref-type="bibr" rid="b77-ijms-11-02715">77</xref>,<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>]. DNA methylation involves the addition of a methyl group at the carbon 5 position of the cytosine ring. The event is reversible and is a significant factor in gene expression [<xref ref-type="bibr" rid="b77-ijms-11-02715">77</xref>,<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>]. It takes place primarily within the 5’CG3’ (also known as the CpG dinucleotide or CpG loci or sites), which are usually depleted and irregularly positioned throughout the genome with weakly concentrated locations. However, more dense areas known as CpG islands also exist [<xref ref-type="bibr" rid="b89-ijms-11-02715">89</xref>,<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b93-ijms-11-02715">93</xref>,<xref ref-type="bibr" rid="b99-ijms-11-02715">99</xref>]. CpG sites are usually methylated whereas the CpG islands are unmethylated. As we age, this mechanism reverses with intermittent methylation of the CpG islands taking place with a corresponding loss of overall methylation patterns throughout the genome; this is prominent with oncogenic events [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b99-ijms-11-02715">99</xref>]. Abnormal or DNA hypermethylation patterns are known to impact promoter regions, which in turn, silence genes and are strongly evident in most cancers. Methylation anomalies also fail concurrently to express many tumor suppressor genes, further contributing to oncogenesis [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b91-ijms-11-02715">91</xref>,<xref ref-type="bibr" rid="b99-ijms-11-02715">99</xref>]. The specific relationship among CpG island hypermethylation activity, genetic alteration, and epigenetic inactivation of tumor suppressor genes is currently being studied in colorectal cancers (CRCs) [<xref ref-type="bibr" rid="b100-ijms-11-02715">100</xref>]. CpG islands exist in about 50% of all human genes within promoter regions, and when hypermethylated, result in transcriptional silencing and tumor suppressor gene activity being down-regulated [<xref ref-type="bibr" rid="b100-ijms-11-02715">100</xref>]. A smaller group of CRCs demonstrate extensive methylation behavior referred to as CpG island methylator phenotype (CIMP). There are three principle mechanisms driving genomic instability in CRCs: 1) CIMP, 2) microsatellite instability (MSI), a unique phenotype within CRC, and 3) chromosomal instability (CIN). All three mechanisms all contribute to epigenetically alter gene expression in CRCs [<xref ref-type="bibr" rid="b101-ijms-11-02715">101</xref>,<xref ref-type="bibr" rid="b102-ijms-11-02715">102</xref>].</p>
<p>DNA methylation is facilitated by DNA methyltransferases (DNMTs), including DNMT 1, DNMT 3A, and DNMT 3B [<xref ref-type="bibr" rid="b92-ijms-11-02715">92</xref>,<xref ref-type="bibr" rid="b99-ijms-11-02715">99</xref>]. Collectively, all three enzymes ensure proper DNA methylation patterns [<xref ref-type="bibr" rid="b95-ijms-11-02715">95</xref>,<xref ref-type="bibr" rid="b99-ijms-11-02715">99</xref>]. DNA methylation (see <xref ref-type="table" rid="t3-ijms-11-02715">Table 3</xref> below) is being studied because cancer cells display elevated levels of altered DNA methylation patterns when compared to normal cells [<xref ref-type="bibr" rid="b77-ijms-11-02715">77</xref>,<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>]. There are a variety of tumor types with associated hypermethylation of at least one gene, including: lung cancer, breast cancer, leukemia, and hematologic diseases [<xref ref-type="bibr" rid="b77-ijms-11-02715">77</xref>,<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>,<xref ref-type="bibr" rid="b94-ijms-11-02715">94</xref>,<xref ref-type="bibr" rid="b96-ijms-11-02715">96</xref>,<xref ref-type="bibr" rid="b97-ijms-11-02715">97</xref>]. Certain patterns of hypomethylation can also contribute to the formation of other cancer types as well, including but not limited to: metastatic hepatocellular cancer, cervical cancer, prostate and B-cell chronic lymphocytic leukemia [<xref ref-type="bibr" rid="b77-ijms-11-02715">77</xref>,<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>,<xref ref-type="bibr" rid="b103-ijms-11-02715">103</xref>–<xref ref-type="bibr" rid="b106-ijms-11-02715">106</xref>]. It has been reported that transcription is impeded when methylcytosine binding domain proteins (MBDs) bind to methylated DNA. This binding process interferes with the interdependent relationship between the DNA methylation and chromatin reconfiguration processes, thereby precluding further gene transcription [<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>,<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>].</p>
<p>An additional study demonstrated that NO<sup>•</sup> regulates chromatin and gene expression through inactivation of nuclear and cytoplasmic proteins by tyrosine-(Tyr) nitration and/or <italic>S</italic>-nitrosylation/nitrosation [<xref ref-type="bibr" rid="b133-ijms-11-02715">133</xref>]. In <italic>S</italic>-nitrosylation, primary, tertiary and quaternary protein architecture is affected [<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>]; in Tyr-nitration, the impact is more widespread across a variety of proteins [<xref ref-type="bibr" rid="b38-ijms-11-02715">38</xref>]. Although NO<sup>•</sup> is diffusible, it must also exist physically within the proper microenvironment and limited macroenvironment with proteins/substrates in order to react. Evidence of this includes the presence of iNOS in the caveolae of endothelial cells, in neurons, and within the nucleus [<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>,<xref ref-type="bibr" rid="b134-ijms-11-02715">134</xref>]. Additionally, it has been suggested that NO<sup>•</sup>, through S-nitrosylation, impacts a number of targets: 1) a variety of transcription factors, including tissue specific transcription factors, 2) some oncoproteins, 3) DNA binding, and 4) transactivation of nuclear receptors [<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>]. NO<sup>•</sup>-mediated changes on transcription factors through Tyr-nitration have also been reported; these changes primarily through impacting normal protein-to-protein interactions and limiting nuclear localization [<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>]. <xref ref-type="table" rid="t4-ijms-11-02715">Table 4</xref> lists the impact of NO<sup>•</sup> on various epigenetic modulators.</p>
<p>It has further been suggested that DNA is susceptible to transition metal-mediated reductive/oxidative modifications which can affect double helix strength [<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>,<xref ref-type="bibr" rid="b135-ijms-11-02715">135</xref>]. Others have hypothesized NO<sup>•</sup> may be impacting a “genome-wide oscillation” and expression/suppression of hundreds of genes, through reactions with thiols/cystine residues in partnership with Fe<sup>2+</sup> ions (both of which are believed to reside in chromatin) [<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>,<xref ref-type="bibr" rid="b136-ijms-11-02715">136</xref>,<xref ref-type="bibr" rid="b137-ijms-11-02715">137</xref>]. This “genome-wide oscillation” could remain in place with oscillating cycles, constructing and deconstructing—of protein complexes, resulting in a corresponding impact on transcription processing [<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>,<xref ref-type="bibr" rid="b138-ijms-11-02715">138</xref>]. Finally, there is evidence to suggest synthesis of NO<sup>•</sup> within the nucleus due to the presence of THB enzymes and two isoforms of NOS (eNOS and iNOS) [<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>,<xref ref-type="bibr" rid="b139-ijms-11-02715">139</xref>].</p></sec>
<sec>
<label>4.2.</label>
<title>MicroRNA</title>
<p>MicroRNAs are relatively small, non-coding RNAs, typically 20–23 nucleotides in size. miRNAs originate from 60–110 nucleotide fold-back RNA precursors [<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>] and have an enormous impact on the control of gene expression [<xref ref-type="bibr" rid="b99-ijms-11-02715">99</xref>,<xref ref-type="bibr" rid="b140-ijms-11-02715">140</xref>,<xref ref-type="bibr" rid="b141-ijms-11-02715">141</xref>]. The biosynthetic pathway originates from proteins of the Argonaute family. These proteins are transcribed first via RNA polymerase II, and then by RNases III Drosha and DGCR8. Finally, in the cytoplasm, RNA III Dicer transforms the proteins into the fully functioning miRNA [<xref ref-type="bibr" rid="b99-ijms-11-02715">99</xref>,<xref ref-type="bibr" rid="b140-ijms-11-02715">140</xref>]. Typically miRNAs act as post-transcriptional regulators by impeding protein production of specific messenger RNA (mRNA) molecular species and apparently interacting through base-pairing between the 5’-end tails of miRNA (nucleotides 2–8) and the anti-parallel sequences of the 3’-untranslated (3’-UTRs) areas within selected mRNAs [<xref ref-type="bibr" rid="b141-ijms-11-02715">141</xref>–<xref ref-type="bibr" rid="b144-ijms-11-02715">144</xref>]. Originally believed to be relatively small in number, there are now over 460 human miRNAs identified [<xref ref-type="bibr" rid="b99-ijms-11-02715">99</xref>], with the possibility of greater than 1,000 in existence [<xref ref-type="bibr" rid="b140-ijms-11-02715">140</xref>]. They have been linked to aberrant cell growth patterns and appear to play a dual role in both oncogenesis and tumor suppression, depending upon which portion of the genome is being affected. For example, the miR-17-92 cluster has a role in tumor neovascularization, when c-myc activates transcription [<xref ref-type="bibr" rid="b145-ijms-11-02715">145</xref>,<xref ref-type="bibr" rid="b146-ijms-11-02715">146</xref>]. This gene is found to be over-expressed in the miR17-92 cluster in B-cell lymphomas and lung cancers. c-Myc also contributes to tumor angiogenesis, as well as tumor growth in mouse B-cell lymphoma [<xref ref-type="bibr" rid="b145-ijms-11-02715">145</xref>–<xref ref-type="bibr" rid="b148-ijms-11-02715">148</xref>]. It has also been demonstrated that human cancer types can be classified using expression patterns of miRNA [<xref ref-type="bibr" rid="b149-ijms-11-02715">149</xref>]. Furthermore, at least one significant relational link has been identified between DNA methylation patterns and miRNA; the strength of this relationship is possibly affected by changing the amounts of DNMT1, DNMT 3A, and/or DNMT 3B present [<xref ref-type="bibr" rid="b98-ijms-11-02715">98</xref>,<xref ref-type="bibr" rid="b150-ijms-11-02715">150</xref>,<xref ref-type="bibr" rid="b151-ijms-11-02715">151</xref>].</p>
<p>As is the case with DNA hypermethylation, regulating the abnormal activity levels of certain miRNAs could be important in initiating and controlling tumorigenesis. It may be possible to target these species through interventions or blocking drugs, such that the miRNAs serve as therapeutic molecular markers. Increasing efforts are also being directed towards providing evidence to support the development of miRNAs as diagnostic and prognostic products [<xref ref-type="bibr" rid="b140-ijms-11-02715">140</xref>]. A few examples include: 1) stimulating apoptosis in cultured glioblastoma cells by deprogramming miR-21 (an oncogenic miRNA) [<xref ref-type="bibr" rid="b152-ijms-11-02715">152</xref>,<xref ref-type="bibr" rid="b153-ijms-11-02715">153</xref>], 2) up-regulating miR-372 and 373 in testicular germ cell tumors [<xref ref-type="bibr" rid="b99-ijms-11-02715">99</xref>,<xref ref-type="bibr" rid="b154-ijms-11-02715">154</xref>], and 3) over-expressing miR-155 in both breast cancers and B-cell lymphomas [<xref ref-type="bibr" rid="b99-ijms-11-02715">99</xref>,<xref ref-type="bibr" rid="b155-ijms-11-02715">155</xref>–<xref ref-type="bibr" rid="b157-ijms-11-02715">157</xref>]. Initial clinical results using epigenetic drugs, such as 4-phenylbutyric acid (PBA) and 5-Aza-2’-deoxycytidine (5-Aza-CdR) exhibit the capability to up-regulate miR-127, which in turn down-regulates Bcl6. This finding provides hope that additional therapeutic options will become available by developing drugs that act via epigenetic mechanisms [<xref ref-type="bibr" rid="b99-ijms-11-02715">99</xref>,<xref ref-type="bibr" rid="b158-ijms-11-02715">158</xref>]. It also suggests that epigenetic drugs may be able to up-regulate tumor-suppressor genes abnormally de-programmed epigenetically, while also causing miRNAs to turn off oncogenic mRNAs [<xref ref-type="bibr" rid="b99-ijms-11-02715">99</xref>,<xref ref-type="bibr" rid="b159-ijms-11-02715">159</xref>].</p>
<p>As research on miRNAs continues to emerge, a number of studies have found a link between NO<sup>•</sup> expression and a number of different miRNAs. In one study, human umbilical vein endothelial cells (HUVECs) were exposed to prolonged unidirectional shear stress, which resulted in the significant up-regulation of 13 miRNAs [<xref ref-type="bibr" rid="b160-ijms-11-02715">160</xref>]. Among the 13 miRNAs identified, miR-21 exhibited the greatest level of up-regulation. miR-21 serves as a regulator of smooth muscle apoptosis [<xref ref-type="bibr" rid="b161-ijms-11-02715">161</xref>] and has been found to be regulated in both cardiac hypertrophy [<xref ref-type="bibr" rid="b162-ijms-11-02715">162</xref>] and human tumors [<xref ref-type="bibr" rid="b163-ijms-11-02715">163</xref>]. Notably, HUVECs which over-expressed miR-21 exhibited increased eNOS phosphorylation and NO<sup>•</sup> production, as well as decreased apoptosis. Similarly, another study found that decreasing the levels of miR-145—another smooth muscle miRNA regulator—resulted in decreased NO<sup>•</sup> expression [<xref ref-type="bibr" rid="b164-ijms-11-02715">164</xref>].</p>
<p>Two other miRNAs have been shown to indirectly modulate iNOS expression: miR-155 and miR-661. Mice transfected with miR-155 exhibited reduced expression of Suppressor of Cytokine Signal-1, and in turn, enhanced iNOS expression [<xref ref-type="bibr" rid="b165-ijms-11-02715">165</xref>]. In a different study, human liver cancer cells expressing the hepatitis B virus transactivator protein HBx were studied [<xref ref-type="bibr" rid="b166-ijms-11-02715">166</xref>]. When the miRNA miR-661 was depleted in these HBx-expressing cells, HBx activity was impaired, leading to enhanced iNOS and nitrite production.</p></sec>
<sec>
<label>4.3.</label>
<title>Histone Modifications</title>
<p>Histones are yet another fundamental epigenetic pathway mechanism and are influential in both transcriptional and post-translational modifications [<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>,<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>]. These proteins are positively attracted to the more negatively charged DNA molecules present, making them particularly susceptible to post-transcriptional changes in DNA binding through: 1) acetylation, 2) methylation, 3) phosphorylation, 4) ubiquitination, 5) SUMOylation (small ubiquinine-like modifier), and 6) isomerization [<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>,<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>]. More specifically, they also include: 1) lysine acetylation, 2) lysine and arginine methylation, 3) serine and threoine phosphorylation, 4) lysine ubiquitylation, and 5) lysine SUMOylation, with over 60 modification sites currently known [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>]. Histone post-translational modifications occur in the globular domains and the amino-terminal tails [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b167-ijms-11-02715">167</xref>,<xref ref-type="bibr" rid="b168-ijms-11-02715">168</xref>], and along with ATP–dependent chromatin remodeling, are among the most significant influencers of gene expression [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>]. Coupled with DNA methylation activities, these histone mechanisms collectively create an adaptive epigenetic environment [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b169-ijms-11-02715">169</xref>]. This is of particular importance towards understanding the enormous impact the histone post-translation changes can have on chromatin steric formation. By altering the molecular landscape, it transforms transcriptional regulators to interact with <italic>cis</italic>-DNA binding elements [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>]. This pattern has been studied and verified in lysine acetylation [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b170-ijms-11-02715">170</xref>].</p>
<p>Histone modification activities take place primarily through two groups of enzymes. The first, histone acetyltranferases (HATs) is comprised of three classes: GNAT, MYST, and CBP/p300. They are characterized by the ability to transfer acetyl groups from acetyl-CoA to amino-ɛ groups for lysines within H3 and H4 and are principally responsible for the opening up of chromatin structure, thereby permitting access for transcription processes to take place [<xref ref-type="bibr" rid="b171-ijms-11-02715">171</xref>]. The second group, histone deacetylases (HADCs) reverse the process, resulting in a tightening or constriction of chromatin, making the epigenome less accessible to reactions [<xref ref-type="bibr" rid="b172-ijms-11-02715">172</xref>]. There are four classes of HDAC enzymes [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>]. Class I consists of HDAC1, HDAC2, HDAC3, and HDAC8. Class II is further divided into two subgroups: IIa, which includes HDAC4, HDAC5, HDAC6, and HDAC7; and IIb, which includes HDAC9 and HDAC10. Class III consists of the sirtuins (SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7) [<xref ref-type="bibr" rid="b173-ijms-11-02715">173</xref>,<xref ref-type="bibr" rid="b174-ijms-11-02715">174</xref>]. Class IV is comprised of one enzyme, HDAC11 [<xref ref-type="bibr" rid="b172-ijms-11-02715">172</xref>,<xref ref-type="bibr" rid="b174-ijms-11-02715">174</xref>]. All play significant roles in human physiology and processes, ranging from embryogenesis and cellular differentiation to tumorigenesis, by facilitating deacetylating enzymatic reactions [<xref ref-type="bibr" rid="b175-ijms-11-02715">175</xref>–<xref ref-type="bibr" rid="b177-ijms-11-02715">177</xref>]. Significantly, HATs are drawn to promoter locations to become part of protein complexes, and many transcriptional co-activators demonstrate HAT enzymatic characteristics [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>]. Co-activators have emerged as a significant participant in chemical signaling between systemic and cellular metabolism, including regulating both mitochondrial oxidative metabolism and the balance between lipid, glucose, and energy homeostatic functionality [<xref ref-type="bibr" rid="b178-ijms-11-02715">178</xref>]. There are a number of other histone modification pathways which we will not explore within the limitations of this review including, but not limited to: 1) histone methyltransferases, 2) lysine and arginine methyltransferases, and 3) non-SET K-methyltransferases. There is synergy and transience between the HATs and HDACs which creates an oscillating-feedback loop and reversible gene transcription control mechanism environment. <xref ref-type="table" rid="t5-ijms-11-02715">Table 5</xref> indicates some of the cancers believed attributable to dysregulated histone protein behavior within the epigenome.</p>
<p>The most recent advances in epigenetic research have been aided by a concurrent evolution of many laboratory techniques, including: 1) cDNA microarray, 2) restriction landmark genomic scanning, 3) CpG island microarrays, and 4) sodium bisulfate conversion [<xref ref-type="bibr" rid="b77-ijms-11-02715">77</xref>,<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>,<xref ref-type="bibr" rid="b179-ijms-11-02715">179</xref>]. Sodium bisulfate is particularly useful in differentiating areas of normal and abnormal methylation activity by converting unmethylated cytosines to uracil, while leaving methylated cytosines intact. There are a number of methods useful in exploring CpG island methylation patterns, including: 1) combined bisulfate restriction analyses, 2) methylation-sensitive single nucleotide extension, 3) methylation-sensitive single-strand conformational polymorphism, and 4) methylation-specific polymerase chain reaction assays [<xref ref-type="bibr" rid="b77-ijms-11-02715">77</xref>,<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>,<xref ref-type="bibr" rid="b179-ijms-11-02715">179</xref>,<xref ref-type="bibr" rid="b180-ijms-11-02715">180</xref>]. Research efforts have also indicated that preemptive assessment of methylation patterns can predict possible malignancies and aid in more timely detection and diagnosis of tumors [<xref ref-type="bibr" rid="b77-ijms-11-02715">77</xref>,<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>].</p>
<p>While much progress has already been made, it is clear that the analytical techniques used to study epigenetics are still evolving. For example, researchers have attempted to analytically differentiate between DNA cytosine methylation (5mC), and hydroxymethylcytosine (hmC). 5mC is involved with transcriptional repression, while the functionality of hmC is still unknown. A recent report concludes the two compounds are “experimentally indistinguishable” from one another using established 5mC mapping criteria and suggest existing 5mC data-bases should be re-examined to ensure that no hmC data has been included erroneously [<xref ref-type="bibr" rid="b181-ijms-11-02715">181</xref>].</p>
<p>To date, only limited data exists regarding the role of NO<sup>•</sup> in histone modification. A recent study has shown that eNOS gene expression relies upon underlying epigenetic causal mechanisms [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>]. It was found that when the human eNOS gene in vascular endothelial cells is expressed, the promoter region is free of DNA methylation, and histone complexes initiate post-transcriptional changes. H3 lysine 4 methylation, H3 lysine 9 acetylation, and H4 lysine 12 acetylation all impacted chromatin by inducing an open steric formation. These reactions thereby permit access by appropriate transcription factors and mechanisms, most important among them, RNA polymerase II at the eNOS promoter location [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>]. In contrast, the iNOS gene was found to be silent in cultured endothelial cells containing hypermethylated CpG dinucleotides within the promoter while they are complexed with the methyl-binding protein, MeCP2. These reactions result in silencing of post-translational histones H3 lysine 9 methylation and are suggested to be prevalent in transcriptionally unexpressed heterochromatin. Sterically, the chromatin structure is tightly configured, and RNA polymerase II is not present [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>]. It is also postulated that this and other studies provide evidence that non-expressing cells have the necessary transcriptional mechanisms to directly affect eNOS expression, and more significantly, a chromatin-linked down-regulating system which prevents eNOS from being expressed in non-endothelial cells [<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b182-ijms-11-02715">182</xref>–<xref ref-type="bibr" rid="b184-ijms-11-02715">184</xref>].</p>
<p>A different study found that the hyporesponsiveness of the iNOS promoter in humans is at least partially due to epigenetic silencing in direct response to the hypermethylation of CpG dinucleotides and histone H3 lysine 9 methylation [<xref ref-type="bibr" rid="b168-ijms-11-02715">168</xref>]. More specifically, the study found that the iNOS promoter was highly methylated at CpG dinucleotides in various human endothelial cells and vascular smooth muscle cells, two cell types in which iNOS induction is known to be difficult. Furthermore, a human pulmonary adenocarcinoma cell line (A549), a colon adenocarcinoma cell line (DLD-1), and primary hepatocyte cell cultures are all capable of iNOS induction [<xref ref-type="bibr" rid="b168-ijms-11-02715">168</xref>]. The iNOS promoter is hypomethylated in DLD-1 cells that have been treated with a DNA methyltransferase. This stimulates both global and iNOS promoter DNA hypomethylation. Use of a chromatin immunoprecipitation assay showed significant presence of methyl-CpG-binding transcriptional repressor MeCP2 within the iNOS promoter location in these endothelial cells. In its entirety the study provided a definition of chromatin-based epigenetic mechanisms controlling human iNOS gene expression [<xref ref-type="bibr" rid="b168-ijms-11-02715">168</xref>].</p></sec></sec>
<sec>
<label>5.</label>
<title>Biological Model System</title>
<p>As indicated earlier in this review, our prior work has focused on the role of NO<sup>•</sup> in both squamous cell carcinomas (head &amp; neck, cervix) and adenocarcinomas (lung, breast). We and others have reported a spectrum of NOS expression in patient populations of these tumors, as well as other tumor types. It has also been observed that patients who present with and/or progress to high levels of NOS expression portend to have poorer clinical outcomes than those with low level expression. It has been hypothesized that immune system cells are being killed by the comparatively high free radical NO<sup>•</sup> environment encountered in the tumor bed [<xref ref-type="bibr" rid="b185-ijms-11-02715">185</xref>]. Since there is no practical way to study this in human patients, we sought to produce a unique, <italic>in vitro</italic> tissue culture model system of free radical stressed tumor cells to determine if in fact they could adapt to increasing levels of NO<sup>•</sup>. The resulting model system would mimic the spectrum of NO<sup>•</sup> expression found clinically [<xref ref-type="bibr" rid="b186-ijms-11-02715">186</xref>].</p>
<p>Our model system was developed by “adapting” low NO<sup>•</sup> expressing cell lines to increasing levels of NO<sup>•</sup> donor. These “parent” cells were gradually exposed to high NO<sup>•</sup> (HNO) levels, resulting in a new set of HNO cell lines. DETA-NONOate was selected as the NO<sup>•</sup> donor for the adaptation process due to: a) its high level of free radical donation (two moles of NO<sup>•</sup> per mole of DETA-NONOate), and relatively long half-life (approximately 24 h. at 37 °C and pH 7.4). During the adaptation process, the cell lines successfully withstood incremental increases of 25 μM DETA-NONOate. For each cell line, the adaptation endpoint was selected as the concentration in which the exogenous NO<sup>•</sup> introduced to the cells was lethal to the parent cell lines. At this endpoint concentration, the HNO cells still grow robustly and are not morphologically altered from the original (untreated) parent cells. Six different parent/HNO cell line pairs have already been developed: one human lung adenocarcinoma cell line (A549) [<xref ref-type="bibr" rid="b186-ijms-11-02715">186</xref>], one mouse lung adenocarcinoma (LP07) [<xref ref-type="bibr" rid="b186-ijms-11-02715">186</xref>], and four human breast adenocarcinomas (T-47D, Hs578t, BT-20, and MCF-7) [<xref ref-type="bibr" rid="b187-ijms-11-02715">187</xref>]. Ongoing work is focusing on extending this model to human head &amp; neck, colon, prostate, and liver tumor cell lines.</p>
<p>While the A549 cells were adapted to DETA-NONOate (see <xref ref-type="fig" rid="f3-ijms-11-02715">Figure 3</xref> below), the A549-HNO cell lines were also found to be resistant to other nitrogen-based free radical donors [<xref ref-type="bibr" rid="b186-ijms-11-02715">186</xref>,<xref ref-type="bibr" rid="b187-ijms-11-02715">187</xref>]. This suggests the A549-HNO cell line could have been generated by using any appropriate NO<sup>•</sup> donor, and that the cells were adapted to the NO<sup>•</sup> free radical, and not the donor per se [<xref ref-type="bibr" rid="b186-ijms-11-02715">186</xref>,<xref ref-type="bibr" rid="b187-ijms-11-02715">187</xref>].</p>
<p>Additionally, the lung and breast tumor HNO cell lines were exposed to various concentrations of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), an oxygen-based free radical donor [<xref ref-type="bibr" rid="b186-ijms-11-02715">186</xref>,<xref ref-type="bibr" rid="b187-ijms-11-02715">187</xref>]. The HNO cell lines were more resistant to exposure than the corresponding parent cell lines (see <xref ref-type="fig" rid="f4-ijms-11-02715">Figure 4</xref> as an example). These results show that the HNO cells are similarly resistant to oxygen-based free radicals.</p>
<p>The reported adaptation process resulted in major biological changes, between the parent and HNO cells despite the identical morphology between the two. HNO cancer cell lines exhibited more aggressive growth than did their corresponding parent cell lines under both normal and low-nutrient growth conditions [<xref ref-type="bibr" rid="b186-ijms-11-02715">186</xref>,<xref ref-type="bibr" rid="b187-ijms-11-02715">187</xref>].</p>
<p>The HNO adapted cell lines are comparable to aggressive, fast growing tumors growing in high NO<sup>•</sup> environments, while the parent cell lines represent less aggressive, slower growing tumors existing in relatively lower NO<sup>•</sup> environments. Furthermore, our adaptation process demonstrated that long-term NO<sup>•</sup> exposure can alter slow growing, less resistant tumors, into faster growing and more resistant cancer cells [<xref ref-type="bibr" rid="b186-ijms-11-02715">186</xref>,<xref ref-type="bibr" rid="b187-ijms-11-02715">187</xref>]. The molecular mechanism for this parent-to-HNO transformation remains to be elucidated; however, high concentration levels of NO<sup>•</sup> (above 1 μM) are known to increase nitrosative cellular stress, which interferes with DNA repair and inhibits zinc finger complexes [<xref ref-type="bibr" rid="b187-ijms-11-02715">187</xref>–<xref ref-type="bibr" rid="b189-ijms-11-02715">189</xref>]. Our model system has proven that tumor cells are able to adapt to comparatively high NO<sup>•</sup> concentrations, regardless of tumor origin or their histological type. Understanding the role of NO<sup>•</sup> in tumor cells may in part lie with NO<sup>•</sup>-mediated epigenetics.</p>
<p>As was discussed above, epigenetic alterations that involve aberrant DNA methylation of CpG sequences in genes is increasingly being recognized as a key mechanism involved in transcriptional silencing of genes in both disease states and, healthy ageing populations [<xref ref-type="bibr" rid="b65-ijms-11-02715">65</xref>,<xref ref-type="bibr" rid="b82-ijms-11-02715">82</xref>,<xref ref-type="bibr" rid="b190-ijms-11-02715">190</xref>]. Our HNO-adapted cell line system provides a robust, <italic>in vitro</italic> model for the identification of novel genetic targets that are associated with antioxidant stress. We also have evidence that, relative to the MCF-7 breast cancer parent cells, the HNO adapted MCF-7 cells demonstrate a significant increase in hypermethylation of both HPP1 (70-fold increase) and APC (22-fold increase) tumor suppressor genes (see <xref ref-type="fig" rid="f5-ijms-11-02715">Figure 5</xref> below).</p></sec>
<sec>
<label>6.</label>
<title>Conclusion</title>
<p>Research of NO<sup>•</sup> has evolved greatly over time. The protective/cytotoxic duality of NO<sup>•</sup>, once in question, is now generally accepted. As such, current studies are now more intently focused on understanding the role of NO<sup>•</sup> in cellular toxicity, particularly as it relates to tumor development and progression. The association between NOS and GST may be a key component of this story, given that over-expression of NOS (regardless of isotype) is often observed in parallel with the over-expression of GST (particularly GST-pi). As discussed above, these results are consistent across a number of different tumor types, suggesting that NO<sup>•</sup> behavior may be more consistent across different tumor types than originally thought. Whether this commonality in NO<sup>•</sup> behavior exists among different tumor types will become more apparent as research is further pursued in the field. The HNO cell line model system described above may prove to be a valuable tool for such studies. Similarly, work will continue in the area of NO<sup>•</sup> and epigenetics. While epigenetic research is still in its infancy, it is already clear that NO<sup>•</sup> may play an important role in a number of epigenetic functions, including DNA methylation, microRNAs, and histone modifications. Thus, while much is already known about the biological role of NO<sup>•</sup>, even more has yet to be discovered.</p></sec></body>
<back>
<ref-list>
<title>References and Notes</title>
<ref id="b1-ijms-11-02715"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furchgott</surname><given-names>RF</given-names></name><name><surname>Zawadzki</surname><given-names>JV</given-names></name></person-group><article-title>The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine</article-title><source>Nature</source><year>1980</year><volume>288</volume><fpage>373</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1038/288373a0</pub-id><pub-id pub-id-type="pmid">6253831</pub-id></citation></ref>
<ref id="b2-ijms-11-02715"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stuehr</surname><given-names>DJ</given-names></name><name><surname>Marletta</surname><given-names>MA</given-names></name></person-group><article-title>Mammalian nitrate biosynthesis: Mouse macrophages produce nitrite and nitrate in response to escherichia coli lipopolysaccharide</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1985</year><volume>82</volume><fpage>7738</fpage><lpage>7742</lpage><pub-id pub-id-type="doi">10.1073/pnas.82.22.7738</pub-id><pub-id pub-id-type="pmid">3906650</pub-id></citation></ref>
<ref id="b3-ijms-11-02715"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacklet</surname><given-names>JW</given-names></name></person-group><article-title>Nitric oxide signaling in invertebrates</article-title><source>Invert. Neurosci</source><year>1997</year><volume>3</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1007/BF02481710</pub-id><pub-id pub-id-type="pmid">9706698</pub-id></citation></ref>
<ref id="b4-ijms-11-02715"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>ID</given-names></name><name><surname>Neill</surname><given-names>SJ</given-names></name><name><surname>Hancock</surname><given-names>JT</given-names></name></person-group><article-title>Nitric oxide synthesis and signalling in plants</article-title><source>Plant Cell Environ</source><year>2008</year><volume>31</volume><fpage>622</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3040.2007.01761.x</pub-id><pub-id pub-id-type="pmid">18034772</pub-id></citation></ref>
<ref id="b5-ijms-11-02715"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Illi</surname><given-names>B</given-names></name><name><surname>Colussi</surname><given-names>C</given-names></name><name><surname>Grasselli</surname><given-names>A</given-names></name><name><surname>Farsetti</surname><given-names>A</given-names></name><name><surname>Capogrossi</surname><given-names>MC</given-names></name><name><surname>Gaetano</surname><given-names>C</given-names></name></person-group><article-title>No sparks off chromatin: Tales of a multifaceted epigenetic regulator</article-title><source>Pharmacol. Ther</source><year>2009</year><volume>123</volume><fpage>344</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2009.05.003</pub-id><pub-id pub-id-type="pmid">19464317</pub-id></citation></ref>
<ref id="b6-ijms-11-02715"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bentz</surname><given-names>BG</given-names></name><name><surname>Simmons</surname><given-names>RL</given-names></name><name><surname>Haines</surname><given-names>GK</given-names><suffix>III</suffix></name><name><surname>Radosevich</surname><given-names>JA</given-names></name></person-group><article-title>The yin and yang of nitric oxide: Reflections on the physiology and pathophysiology of no</article-title><source>Head Neck</source><year>2000</year><volume>22</volume><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0347(200001)22:1&lt;71::AID-HED11&gt;3.0.CO;2-G</pub-id><pub-id pub-id-type="pmid">10585608</pub-id></citation></ref>
<ref id="b7-ijms-11-02715"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mocellin</surname><given-names>S</given-names></name><name><surname>Bronte</surname><given-names>V</given-names></name><name><surname>Nitti</surname><given-names>D</given-names></name></person-group><article-title>Nitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities</article-title><source>Med. Res. Rev</source><year>2007</year><volume>27</volume><fpage>317</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1002/med.20092</pub-id><pub-id pub-id-type="pmid">16991100</pub-id></citation></ref>
<ref id="b8-ijms-11-02715"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><article-title>Redox signaling: Nitrosylation and related target interactions of nitric oxide</article-title><source>Cell</source><year>1994</year><volume>78</volume><fpage>931</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(94)90269-0</pub-id><pub-id pub-id-type="pmid">7923362</pub-id></citation></ref>
<ref id="b9-ijms-11-02715"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hibbs</surname><given-names>JB</given-names></name><name><surname>Vavrin</surname><given-names>A</given-names></name><name><surname>Taintor</surname><given-names>RR</given-names></name></person-group><article-title>L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells</article-title><source>J. Immunol</source><year>1987</year><volume>138</volume><fpage>550</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">2432129</pub-id></citation></ref>
<ref id="b10-ijms-11-02715"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langrehr</surname><given-names>JM</given-names></name><name><surname>Hoffman</surname><given-names>RA</given-names></name><name><surname>Lancaster</surname><given-names>JR</given-names><suffix>Jr</suffix></name><name><surname>Simmons</surname><given-names>RL</given-names></name></person-group><article-title>Nitric oxide--a new endogenous immunomodulator</article-title><source>Transplantation</source><year>1993</year><volume>55</volume><fpage>1205</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1097/00007890-199306000-00001</pub-id><pub-id pub-id-type="pmid">8516803</pub-id></citation></ref>
<ref id="b11-ijms-11-02715"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garthwaite</surname><given-names>J</given-names></name></person-group><article-title>Concepts of neural nitric oxide-mediated transmission</article-title><source>Eur. J. Neurosci</source><year>2008</year><volume>27</volume><fpage>2783</fpage><lpage>2802</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06285.x</pub-id><pub-id pub-id-type="pmid">18588525</pub-id></citation></ref>
<ref id="b12-ijms-11-02715"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zacharek</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Kapke</surname><given-names>A</given-names></name><name><surname>Chopp</surname><given-names>M</given-names></name></person-group><article-title>Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice</article-title><source>J. Neurosci</source><year>2005</year><volume>25</volume><fpage>2366</fpage><lpage>2375</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5071-04.2005</pub-id><pub-id pub-id-type="pmid">15745963</pub-id></citation></ref>
<ref id="b13-ijms-11-02715"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goud</surname><given-names>AP</given-names></name><name><surname>Goud</surname><given-names>PT</given-names></name><name><surname>Diamond</surname><given-names>MP</given-names></name><name><surname>Abu-Soud</surname><given-names>HM</given-names></name></person-group><article-title>Nitric oxide delays oocyte aging</article-title><source>Biochemistry</source><year>2005</year><volume>44</volume><fpage>11361</fpage><lpage>11368</lpage><pub-id pub-id-type="doi">10.1021/bi050711f</pub-id><pub-id pub-id-type="pmid">16114873</pub-id></citation></ref>
<ref id="b14-ijms-11-02715"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stamler</surname><given-names>JS</given-names></name><name><surname>Meissner</surname><given-names>G</given-names></name></person-group><article-title>Physiology of nitric oxide in skeletal muscle</article-title><source>Physiol. Rev</source><year>2001</year><volume>81</volume><fpage>209</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">11152758</pub-id></citation></ref>
<ref id="b15-ijms-11-02715"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>CC</given-names></name><name><surname>Agoston</surname><given-names>H</given-names></name><name><surname>Beier</surname><given-names>F</given-names></name></person-group><article-title>Nitric oxide, c-type natriuretic peptide and cgmp as regulators of endochondral ossification</article-title><source>Dev. Biol</source><year>2008</year><volume>319</volume><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2008.04.031</pub-id><pub-id pub-id-type="pmid">18514181</pub-id></citation></ref>
<ref id="b16-ijms-11-02715"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Yano</surname><given-names>K</given-names></name><name><surname>Matsui-Hirai</surname><given-names>H</given-names></name><name><surname>Yokoo</surname><given-names>H</given-names></name><name><surname>Hattori</surname><given-names>Y</given-names></name><name><surname>Iguchi</surname><given-names>A</given-names></name></person-group><article-title>Nitric oxide and endothelial cellular senescence</article-title><source>Pharmacol. Ther</source><year>2008</year><volume>120</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.09.002</pub-id><pub-id pub-id-type="pmid">18930078</pub-id></citation></ref>
<ref id="b17-ijms-11-02715"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spinetti</surname><given-names>G</given-names></name><name><surname>Kraenkel</surname><given-names>N</given-names></name><name><surname>Emanueli</surname><given-names>C</given-names></name><name><surname>Madeddu</surname><given-names>P</given-names></name></person-group><article-title>Diabetes and vessel wall remodelling: From mechanistic insights to regenerative therapies</article-title><source>Cardiovasc. Res</source><year>2008</year><volume>78</volume><fpage>265</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvn039</pub-id><pub-id pub-id-type="pmid">18281374</pub-id></citation></ref>
<ref id="b18-ijms-11-02715"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>DD</given-names></name><name><surname>Espey</surname><given-names>MG</given-names></name><name><surname>Ridnour</surname><given-names>LA</given-names></name><name><surname>Hofseth</surname><given-names>LJ</given-names></name><name><surname>Mancardi</surname><given-names>D</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name><name><surname>Wink</surname><given-names>DA</given-names></name></person-group><article-title>Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>8894</fpage><lpage>8899</lpage><pub-id pub-id-type="doi">10.1073/pnas.0400453101</pub-id><pub-id pub-id-type="pmid">15178764</pub-id></citation></ref>
<ref id="b19-ijms-11-02715"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridnour</surname><given-names>LA</given-names></name><name><surname>Thomas</surname><given-names>DD</given-names></name><name><surname>Mancardi</surname><given-names>D</given-names></name><name><surname>Espey</surname><given-names>MG</given-names></name><name><surname>Miranda</surname><given-names>KM</given-names></name><name><surname>Paolocci</surname><given-names>N</given-names></name><name><surname>Feelisch</surname><given-names>M</given-names></name><name><surname>Fukuto</surname><given-names>J</given-names></name><name><surname>Wink</surname><given-names>DA</given-names></name></person-group><article-title>The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations</article-title><source>Biol. Chem</source><year>2004</year><volume>385</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1515/BC.2004.001</pub-id><pub-id pub-id-type="pmid">14977040</pub-id></citation></ref>
<ref id="b20-ijms-11-02715"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Kuncewicz</surname><given-names>T</given-names></name><name><surname>Dubinsky</surname><given-names>WP</given-names></name><name><surname>Kone</surname><given-names>BC</given-names></name></person-group><article-title>Nitric oxide-dependent negative feedback of parp-1 trans-activation of the inducible nitric-oxide synthase gene</article-title><source>J. Biol. Chem</source><year>2006</year><volume>281</volume><fpage>9101</fpage><lpage>9109</lpage><pub-id pub-id-type="pmid">16464859</pub-id></citation></ref>
<ref id="b21-ijms-11-02715"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mocellin</surname><given-names>S</given-names></name></person-group><article-title>Nitric oxide: Cancer target or anticancer agent?</article-title><source>Curr. Cancer Drug Targets</source><year>2009</year><volume>9</volume><fpage>214</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.2174/156800909787581015</pub-id><pub-id pub-id-type="pmid">19275761</pub-id></citation></ref>
<ref id="b22-ijms-11-02715"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>QS</given-names></name><name><surname>Goh</surname><given-names>V</given-names></name><name><surname>Milner</surname><given-names>J</given-names></name><name><surname>Stratford</surname><given-names>MR</given-names></name><name><surname>Folkes</surname><given-names>LK</given-names></name><name><surname>Tozer</surname><given-names>GM</given-names></name><name><surname>Saunders</surname><given-names>MI</given-names></name><name><surname>Hoskin</surname><given-names>PJ</given-names></name></person-group><article-title>Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: A phase I study</article-title><source>Lancet Oncol</source><year>2007</year><volume>8</volume><fpage>111</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(07)70001-3</pub-id><pub-id pub-id-type="pmid">17267325</pub-id></citation></ref>
<ref id="b23-ijms-11-02715"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gratton</surname><given-names>JP</given-names></name><name><surname>Lin</surname><given-names>MI</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Weiss</surname><given-names>ED</given-names></name><name><surname>Jiang</surname><given-names>ZL</given-names></name><name><surname>Fairchild</surname><given-names>TA</given-names></name><name><surname>Iwakiri</surname><given-names>Y</given-names></name><name><surname>Groszmann</surname><given-names>R</given-names></name><name><surname>Claffey</surname><given-names>KP</given-names></name><name><surname>Cheng</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice</article-title><source>Cancer Cell</source><year>2003</year><volume>4</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(03)00168-5</pub-id><pub-id pub-id-type="pmid">12892711</pub-id></citation></ref>
<ref id="b24-ijms-11-02715"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murohara</surname><given-names>T</given-names></name><name><surname>Asahara</surname><given-names>T</given-names></name><name><surname>Silver</surname><given-names>M</given-names></name><name><surname>Bauters</surname><given-names>C</given-names></name><name><surname>Masuda</surname><given-names>H</given-names></name><name><surname>Kalka</surname><given-names>C</given-names></name><name><surname>Kearney</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Symes</surname><given-names>JF</given-names></name><name><surname>Fishman</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Nitric oxide synthase modulates angiogenesis in response to tissue ischemia</article-title><source>J. Clin. Invest</source><year>1998</year><volume>101</volume><fpage>2567</fpage><lpage>2578</lpage><pub-id pub-id-type="doi">10.1172/JCI1560</pub-id><pub-id pub-id-type="pmid">9616228</pub-id></citation></ref>
<ref id="b25-ijms-11-02715"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papapetropoulos</surname><given-names>A</given-names></name><name><surname>Garcia-Cardena</surname><given-names>G</given-names></name><name><surname>Madri</surname><given-names>JA</given-names></name><name><surname>Sessa</surname><given-names>WC</given-names></name></person-group><article-title>Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells</article-title><source>J. Clin. Invest</source><year>1997</year><volume>100</volume><fpage>3131</fpage><lpage>3139</lpage><pub-id pub-id-type="doi">10.1172/JCI119868</pub-id><pub-id pub-id-type="pmid">9399960</pub-id></citation></ref>
<ref id="b26-ijms-11-02715"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crowell</surname><given-names>JA</given-names></name><name><surname>Steele</surname><given-names>VE</given-names></name><name><surname>Sigman</surname><given-names>CC</given-names></name><name><surname>Fay</surname><given-names>JR</given-names></name></person-group><article-title>Is inducible nitric oxide synthase a target for chemoprevention?</article-title><source>Mol. Cancer Ther</source><year>2003</year><volume>2</volume><fpage>815</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">12939472</pub-id></citation></ref>
<ref id="b27-ijms-11-02715"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hofseth</surname><given-names>LJ</given-names></name><name><surname>Hussain</surname><given-names>SP</given-names></name><name><surname>Wogan</surname><given-names>GN</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name></person-group><article-title>Nitric oxide in cancer and chemoprevention</article-title><source>Free Radic. Biol. Med</source><year>2003</year><volume>34</volume><fpage>955</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1016/S0891-5849(02)01363-1</pub-id><pub-id pub-id-type="pmid">12684081</pub-id></citation></ref>
<ref id="b28-ijms-11-02715"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tozer</surname><given-names>GM</given-names></name><name><surname>Prise</surname><given-names>VE</given-names></name><name><surname>Chaplin</surname><given-names>DJ</given-names></name></person-group><article-title>Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with l-arginine</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>948</fpage><lpage>955</lpage><pub-id pub-id-type="pmid">9041200</pub-id></citation></ref>
<ref id="b29-ijms-11-02715"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haynes</surname><given-names>WG</given-names></name><name><surname>Noon</surname><given-names>JP</given-names></name><name><surname>Walker</surname><given-names>BR</given-names></name><name><surname>Webb</surname><given-names>DJ</given-names></name></person-group><article-title>Inhibition of nitric oxide synthesis increases blood pressure in healthy humans</article-title><source>J. Hypertens</source><year>1993</year><volume>11</volume><fpage>1375</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.1097/00004872-199312000-00009</pub-id><pub-id pub-id-type="pmid">7510736</pub-id></citation></ref>
<ref id="b30-ijms-11-02715"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lorente</surname><given-names>JA</given-names></name><name><surname>Landin</surname><given-names>L</given-names></name><name><surname>De Pablo</surname><given-names>R</given-names></name><name><surname>Renes</surname><given-names>E</given-names></name><name><surname>Liste</surname><given-names>D</given-names></name></person-group><article-title>L-arginine pathway in the sepsis syndrome</article-title><source>Crit. Care Med</source><year>1993</year><volume>21</volume><fpage>1287</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1097/00003246-199309000-00010</pub-id><pub-id pub-id-type="pmid">8370291</pub-id></citation></ref>
<ref id="b31-ijms-11-02715"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bentz</surname><given-names>BG</given-names></name><name><surname>Haines</surname><given-names>GK</given-names><suffix>III</suffix></name><name><surname>Radosevich</surname><given-names>JA</given-names></name></person-group><article-title>Increased protein nitrosylation in head and neck squamous cell carcinoma</article-title><source>Head Neck</source><year>2000</year><volume>22</volume><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0347(200001)22:1&lt;64::AID-HED10&gt;3.0.CO;2-J</pub-id><pub-id pub-id-type="pmid">10585607</pub-id></citation></ref>
<ref id="b32-ijms-11-02715"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>DC</given-names></name><name><surname>Charles</surname><given-names>IG</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Moss</surname><given-names>DW</given-names></name><name><surname>Holmes</surname><given-names>LS</given-names></name><name><surname>Baylis</surname><given-names>SA</given-names></name><name><surname>Rhodes</surname><given-names>P</given-names></name><name><surname>Westmore</surname><given-names>K</given-names></name><name><surname>Emson</surname><given-names>PC</given-names></name><name><surname>Moncada</surname><given-names>S</given-names></name></person-group><article-title>Roles of nitric oxide in tumor growth</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1995</year><volume>92</volume><fpage>4392</fpage><lpage>4396</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.10.4392</pub-id><pub-id pub-id-type="pmid">7538668</pub-id></citation></ref>
<ref id="b33-ijms-11-02715"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Epperlein</surname><given-names>MM</given-names></name><name><surname>Nourooz-Zadeh</surname><given-names>J</given-names></name><name><surname>Noronha-Dutra</surname><given-names>AA</given-names></name><name><surname>Woolf</surname><given-names>N</given-names></name></person-group><article-title>Nitric oxide in cigarette smoke as a mediator of oxidative damage</article-title><source>Int. J. Exp. Pathol</source><year>1996</year><volume>77</volume><fpage>197</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">8977370</pub-id></citation></ref>
<ref id="b34-ijms-11-02715"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaston</surname><given-names>B</given-names></name><name><surname>Drazen</surname><given-names>JM</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><article-title>The biology of nitrogen oxides in the airways</article-title><source>Am. J. Respir. Crit. Care Med</source><year>1994</year><volume>149</volume><fpage>538</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">7508323</pub-id></citation></ref>
<ref id="b35-ijms-11-02715"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mirvish</surname><given-names>SS</given-names></name></person-group><article-title>Role of n-nitroso compounds (noc) and n-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to noc</article-title><source>Cancer Lett</source><year>1995</year><volume>93</volume><fpage>17</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/0304-3835(95)03786-V</pub-id><pub-id pub-id-type="pmid">7600541</pub-id></citation></ref>
<ref id="b36-ijms-11-02715"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>QH</given-names></name><name><surname>Roughton</surname><given-names>FJ</given-names></name></person-group><article-title>The determination of the velocity constants of four successive reactions of carbon monoxide with sheep haemoglobin</article-title><source>Proc Soc Ser B: Biol Sci Lond</source><year>1957</year><fpage>206</fpage><lpage>224</lpage></citation></ref>
<ref id="b37-ijms-11-02715"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>KL</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Turko</surname><given-names>IV</given-names></name><name><surname>Murad</surname><given-names>F</given-names></name></person-group><article-title>Novel effects of nitric oxide</article-title><source>Annu. Rev. Pharmacol. Toxicol</source><year>2001</year><volume>41</volume><fpage>203</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.41.1.203</pub-id><pub-id pub-id-type="pmid">11264456</pub-id></citation></ref>
<ref id="b38-ijms-11-02715"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>JM</given-names></name><name><surname>Peluffo</surname><given-names>G</given-names></name><name><surname>Radi</surname><given-names>R</given-names></name></person-group><article-title>Protein tyrosine nitration--functional alteration or just a biomarker?</article-title><source>Free Radic. Biol. Med</source><year>2008</year><volume>45</volume><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2008.04.010</pub-id><pub-id pub-id-type="pmid">18460345</pub-id></citation></ref>
<ref id="b39-ijms-11-02715"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>AP</given-names></name><name><surname>Prazma</surname><given-names>J</given-names></name><name><surname>Baggett</surname><given-names>HC</given-names></name><name><surname>Rose</surname><given-names>AS</given-names></name><name><surname>Pillsbury</surname><given-names>HC</given-names></name></person-group><article-title>Nitric oxide is a mediator of neurogenic vascular exudation in the nose</article-title><source>Otolaryngol. Head Neck. Surg</source><year>1997</year><volume>116</volume><fpage>294</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/S0194-5998(97)70263-8</pub-id><pub-id pub-id-type="pmid">9121780</pub-id></citation></ref>
<ref id="b40-ijms-11-02715"><label>40.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>O</given-names></name><name><surname>Bloch</surname><given-names>W</given-names></name><name><surname>Rocker</surname><given-names>J</given-names></name></person-group><article-title>Nos-mapping of human nasal mucosa under physiologic and pathophysiological conditions</article-title><source>Proceedings of the Fourth International Meeting on the Biology of Nitric Oxide</source><person-group person-group-type="editor"><name><surname>Moncada</surname><given-names>S</given-names></name><name><surname>Stamler</surname><given-names>J</given-names></name><name><surname>Gross</surname><given-names>S</given-names></name><name><surname>Higgs</surname><given-names>EA</given-names></name></person-group><publisher-name>Portland Press</publisher-name><publisher-loc>London, UK</publisher-loc><year>1996</year>230</citation></ref>
<ref id="b41-ijms-11-02715"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eaton</surname><given-names>DL</given-names></name><name><surname>Bammler</surname><given-names>TK</given-names></name></person-group><article-title>Concise review of the glutathione s-transferases and their significance to toxicology</article-title><source>Toxicol. Sci</source><year>1999</year><volume>49</volume><fpage>156</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1093/toxsci/49.2.156</pub-id><pub-id pub-id-type="pmid">10416260</pub-id></citation></ref>
<ref id="b42-ijms-11-02715"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanna</surname><given-names>E</given-names></name><name><surname>MacLeod</surname><given-names>S</given-names></name><name><surname>Vural</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>N</given-names></name></person-group><article-title>Genetic deletions of glutathione-s-transferase as a risk factor in squamous cell carcinoma of the larynx: A preliminary report</article-title><source>Am. J. Otolaryngol</source><year>2001</year><volume>22</volume><fpage>121</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1053/ajot.2001.22571</pub-id><pub-id pub-id-type="pmid">11283827</pub-id></citation></ref>
<ref id="b43-ijms-11-02715"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ketterer</surname><given-names>B</given-names></name></person-group><article-title>Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis</article-title><source>Mutat. Res</source><year>1988</year><volume>202</volume><fpage>343</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/0027-5107(88)90197-2</pub-id><pub-id pub-id-type="pmid">3057366</pub-id></citation></ref>
<ref id="b44-ijms-11-02715"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mulder</surname><given-names>TP</given-names></name><name><surname>Manni</surname><given-names>JJ</given-names></name><name><surname>Roelofs</surname><given-names>HM</given-names></name><name><surname>Peters</surname><given-names>WH</given-names></name><name><surname>Wiersma</surname><given-names>A</given-names></name></person-group><article-title>Glutatione s-transferases and glutathione in human head and neck cancer</article-title><source>Carcinogenesis</source><year>1995</year><volume>16</volume><fpage>619</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1093/carcin/16.3.619</pub-id><pub-id pub-id-type="pmid">7697822</pub-id></citation></ref>
<ref id="b45-ijms-11-02715"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McIlwain</surname><given-names>CC</given-names></name><name><surname>Townsend</surname><given-names>DM</given-names></name><name><surname>Tew</surname><given-names>KD</given-names></name></person-group><article-title>Glutathione s-transferase polymorphisms: Cancer incidence and therapy</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>1639</fpage><lpage>1648</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209373</pub-id><pub-id pub-id-type="pmid">16550164</pub-id></citation></ref>
<ref id="b46-ijms-11-02715"><label>46.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schumaker</surname><given-names>L</given-names></name><name><surname>Nikitakis</surname><given-names>N</given-names></name><name><surname>Goloubeva</surname><given-names>O</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>R</given-names></name><name><surname>Cullen</surname><given-names>KJ</given-names></name></person-group><article-title>Elevated expression of glutathione s-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone</article-title><source>Clin. Cancer Res</source><year>2008</year><volume>14</volume><fpage>5877</fpage><lpage>5883</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0998</pub-id><pub-id pub-id-type="pmid">18794100</pub-id></citation></ref>
<ref id="b47-ijms-11-02715"><label>47.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ali-Osman</surname><given-names>F</given-names></name><name><surname>Akande</surname><given-names>O</given-names></name><name><surname>Antoun</surname><given-names>G</given-names></name><name><surname>Mao</surname><given-names>JX</given-names></name><name><surname>Buolamwini</surname><given-names>J</given-names></name></person-group><article-title>Molecular cloning, characterization, and expression in escherichia coli of full-length cdnas of three human glutathione s-transferase pi gene variants. Evidence for differential catalytic activity of the encoded proteins</article-title><source>J. Biol. Chem</source><year>1997</year><volume>272</volume><fpage>10004</fpage><lpage>10012</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.15.10004</pub-id><pub-id pub-id-type="pmid">9092542</pub-id></citation></ref>
<ref id="b48-ijms-11-02715"><label>48.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Iida</surname><given-names>T</given-names></name><name><surname>Cho</surname><given-names>S</given-names></name><name><surname>Oka</surname><given-names>M</given-names></name><name><surname>Kohno</surname><given-names>S</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name></person-group><article-title>Overexpression of glutathione s-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells</article-title><source>Free Radic. Res</source><year>1999</year><volume>31</volume><fpage>549</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1080/10715769900301121</pub-id><pub-id pub-id-type="pmid">10630679</pub-id></citation></ref>
<ref id="b49-ijms-11-02715"><label>49.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoehlmacher</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>DJ</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Groshen</surname><given-names>S</given-names></name><name><surname>Tsao-Wei</surname><given-names>DD</given-names></name><name><surname>Yu</surname><given-names>MC</given-names></name><name><surname>Lenz</surname><given-names>HJ</given-names></name></person-group><article-title>Association between glutathione s-transferase p1, t1, and m1 genetic polymorphism and survival of patients with metastatic colorectal cancer</article-title><source>J. Natl. Cancer Inst</source><year>2002</year><volume>94</volume><fpage>936</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1093/jnci/94.12.936</pub-id><pub-id pub-id-type="pmid">12072547</pub-id></citation></ref>
<ref id="b50-ijms-11-02715"><label>50.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maugard</surname><given-names>CM</given-names></name><name><surname>Charrier</surname><given-names>J</given-names></name><name><surname>Pitard</surname><given-names>A</given-names></name><name><surname>Campion</surname><given-names>L</given-names></name><name><surname>Akande</surname><given-names>O</given-names></name><name><surname>Pleasants</surname><given-names>L</given-names></name><name><surname>Ali-Osman</surname><given-names>F</given-names></name></person-group><article-title>Genetic polymorphism at the glutathione s-transferase (gst) p1 locus is a breast cancer risk modifier</article-title><source>Int. J. Cancer</source><year>2001</year><volume>91</volume><fpage>334</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1057&gt;3.0.CO;2-H</pub-id><pub-id pub-id-type="pmid">11169956</pub-id></citation></ref>
<ref id="b51-ijms-11-02715"><label>51.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tew</surname><given-names>KD</given-names></name></person-group><article-title>Glutathione-associated enzymes in anticancer drug resistance</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>4313</fpage><lpage>4320</lpage><pub-id pub-id-type="pmid">8044778</pub-id></citation></ref>
<ref id="b52-ijms-11-02715"><label>52.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miura</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Tanita</surname><given-names>J</given-names></name><name><surname>Shinkawa</surname><given-names>H</given-names></name><name><surname>Satoh</surname><given-names>K</given-names></name><name><surname>Tsuchida</surname><given-names>S</given-names></name></person-group><article-title>Correlated expression of glutathione s-transferase-pi and c-jun or other oncogene products in human squamous cell carcinomas of the head and neck: Relevance to relapse after radiation therapy</article-title><source>Jpn. J. Cancer Res</source><year>1997</year><volume>88</volume><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.1997.tb00359.x</pub-id><pub-id pub-id-type="pmid">9119742</pub-id></citation></ref>
<ref id="b53-ijms-11-02715"><label>53.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bongers</surname><given-names>V</given-names></name><name><surname>Snow</surname><given-names>GB</given-names></name><name><surname>de Vries</surname><given-names>N</given-names></name><name><surname>Cattan</surname><given-names>AR</given-names></name><name><surname>Hall</surname><given-names>AG</given-names></name><name><surname>van der Waal</surname><given-names>I</given-names></name><name><surname>Braakhuis</surname><given-names>BJ</given-names></name></person-group><article-title>Second primary head and neck squamous cell carcinoma predicted by the glutathione s-transferase expression in healthy tissue in the direct vicinity of the first tumor</article-title><source>Lab. Invest</source><year>1995</year><volume>73</volume><fpage>503</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">7474922</pub-id></citation></ref>
<ref id="b54-ijms-11-02715"><label>54.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bentz</surname><given-names>BG</given-names></name><name><surname>Haines</surname><given-names>GK</given-names><suffix>III</suffix></name><name><surname>Lingen</surname><given-names>MW</given-names></name><name><surname>Pelzer</surname><given-names>HJ</given-names></name><name><surname>Hanson</surname><given-names>DG</given-names></name><name><surname>Radosevich</surname><given-names>JA</given-names></name></person-group><article-title>Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck</article-title><source>Ann. Otol. Rhinol. Laryngol</source><year>1999</year><volume>108</volume><fpage>781</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">10453787</pub-id></citation></ref>
<ref id="b55-ijms-11-02715"><label>55.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bentz</surname><given-names>BG</given-names></name><name><surname>Haines</surname><given-names>GK</given-names><suffix>III</suffix></name><name><surname>Radosevich</surname><given-names>JA</given-names></name></person-group><article-title>Glutathione s-transferase pi in squamous cell carcinoma of the head and neck</article-title><source>Laryngoscope</source><year>2000</year><volume>110</volume><fpage>1642</fpage><lpage>1647</lpage><pub-id pub-id-type="doi">10.1097/00005537-200010000-00013</pub-id><pub-id pub-id-type="pmid">11037818</pub-id></citation></ref>
<ref id="b56-ijms-11-02715"><label>56.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bentz</surname><given-names>BG</given-names></name><name><surname>Haines</surname><given-names>GK</given-names><suffix>III</suffix></name><name><surname>Lingen</surname><given-names>MW</given-names></name><name><surname>Pelzer</surname><given-names>HJ</given-names></name><name><surname>Hanson</surname><given-names>DG</given-names></name><name><surname>Radosevich</surname><given-names>JA</given-names></name></person-group><article-title>Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck</article-title><source>Ann. Otol. Rhinol. Laryngol</source><year>1999</year><volume>108</volume><fpage>781</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">10453787</pub-id></citation></ref>
<ref id="b57-ijms-11-02715"><label>57.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bentz</surname><given-names>BG</given-names></name><name><surname>Haines</surname><given-names>GK</given-names><suffix>III</suffix></name><name><surname>Radosevich</surname><given-names>JA</given-names></name></person-group><article-title>Glutathione s-transferase pi in squamous cell carcinoma of the head and neck</article-title><source>Laryngoscope</source><year>2000</year><volume>110</volume><fpage>1642</fpage><lpage>1647</lpage><pub-id pub-id-type="doi">10.1097/00005537-200010000-00013</pub-id><pub-id pub-id-type="pmid">11037818</pub-id></citation></ref>
<ref id="b58-ijms-11-02715"><label>58.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Gravitt</surname><given-names>PE</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Maldonado</surname><given-names>AM</given-names></name><name><surname>Ozbun</surname><given-names>MA</given-names></name></person-group><article-title>Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>4878</fpage><lpage>4884</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4695</pub-id><pub-id pub-id-type="pmid">19487298</pub-id></citation></ref>
<ref id="b59-ijms-11-02715"><label>59.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benencia</surname><given-names>F</given-names></name><name><surname>Gamba</surname><given-names>G</given-names></name><name><surname>Cavalieri</surname><given-names>H</given-names></name><name><surname>Courreges</surname><given-names>MC</given-names></name><name><surname>Benedetti</surname><given-names>R</given-names></name><name><surname>Villamil</surname><given-names>SM</given-names></name><name><surname>Massouh</surname><given-names>EJ</given-names></name></person-group><article-title>Nitric oxide and hsv vaginal infection in balb/c mice</article-title><source>Virology</source><year>2003</year><volume>309</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/S0042-6822(02)00057-0</pub-id><pub-id pub-id-type="pmid">12726728</pub-id></citation></ref>
<ref id="b60-ijms-11-02715"><label>60.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carratelli</surname><given-names>CR</given-names></name><name><surname>Rizzo</surname><given-names>A</given-names></name><name><surname>Paolillo</surname><given-names>R</given-names></name><name><surname>Catania</surname><given-names>MR</given-names></name><name><surname>Catalanotti</surname><given-names>P</given-names></name><name><surname>Rossano</surname><given-names>F</given-names></name></person-group><article-title>Effect of nitric oxide on the growth of chlamydophila pneumoniae</article-title><source>Can. J. Microbiol</source><year>2005</year><volume>51</volume><fpage>941</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1139/w05-080</pub-id><pub-id pub-id-type="pmid">16333333</pub-id></citation></ref>
<ref id="b61-ijms-11-02715"><label>61.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>K</given-names></name><name><surname>Lubo</surname><given-names>Z</given-names></name></person-group><article-title>Review article: Steroid hormones and uterine vascular adaptation to pregnancy</article-title><source>Reprod. Sci</source><year>2008</year><volume>15</volume><fpage>336</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1177/1933719108317975</pub-id><pub-id pub-id-type="pmid">18497342</pub-id></citation></ref>
<ref id="b62-ijms-11-02715"><label>62.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hiraku</surname><given-names>Y</given-names></name><name><surname>Tabata</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><name><surname>Murata</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Kawanishi</surname><given-names>S</given-names></name></person-group><article-title>Nitrative and oxidative DNA damage in cervical intraepithelial neoplasia associated with human papilloma virus infection</article-title><source>Cancer Sci</source><year>2007</year><volume>98</volume><fpage>964</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2007.00497.x</pub-id><pub-id pub-id-type="pmid">17488337</pub-id></citation></ref>
<ref id="b63-ijms-11-02715"><label>63.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tavares-Murta</surname><given-names>BM</given-names></name><name><surname>de Resende</surname><given-names>AD</given-names></name><name><surname>Cunha</surname><given-names>FQ</given-names></name><name><surname>Murta</surname><given-names>EF</given-names></name></person-group><article-title>Local profile of cytokines and nitric oxide in patients with bacterial vaginosis and cervical intraepithelial neoplasia</article-title><source>Eur. J. Obstet. Gynecol. Reprod. Biol</source><year>2008</year><volume>138</volume><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.ejogrb.2007.06.015</pub-id><pub-id pub-id-type="pmid">17683845</pub-id></citation></ref>
<ref id="b64-ijms-11-02715"><label>64.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cerutti</surname><given-names>PA</given-names></name></person-group><article-title>Prooxidant states and tumor promotion</article-title><source>Science</source><year>1985</year><volume>227</volume><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1126/science.2981433</pub-id><pub-id pub-id-type="pmid">2981433</pub-id></citation></ref>
<ref id="b65-ijms-11-02715"><label>65.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>SP</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name></person-group><article-title>Inflammation and cancer: An ancient link with novel potentials</article-title><source>Int. J. Cancer</source><year>2007</year><volume>121</volume><fpage>2373</fpage><lpage>2380</lpage><pub-id pub-id-type="doi">10.1002/ijc.23173</pub-id><pub-id pub-id-type="pmid">17893866</pub-id></citation></ref>
<ref id="b66-ijms-11-02715"><label>66.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>SP</given-names></name><name><surname>Raja</surname><given-names>K</given-names></name><name><surname>Amstad</surname><given-names>PA</given-names></name><name><surname>Sawyer</surname><given-names>M</given-names></name><name><surname>Trudel</surname><given-names>LJ</given-names></name><name><surname>Wogan</surname><given-names>GN</given-names></name><name><surname>Hofseth</surname><given-names>LJ</given-names></name><name><surname>Shields</surname><given-names>PG</given-names></name><name><surname>Billiar</surname><given-names>TR</given-names></name><name><surname>Trautwein</surname><given-names>C</given-names></name><etal/></person-group><article-title>Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: Oxyradical overload diseases</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2000</year><volume>97</volume><fpage>12770</fpage><lpage>12775</lpage><pub-id pub-id-type="doi">10.1073/pnas.220416097</pub-id><pub-id pub-id-type="pmid">11050162</pub-id></citation></ref>
<ref id="b67-ijms-11-02715"><label>67.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>J</given-names></name><name><surname>Gansauge</surname><given-names>F</given-names></name><name><surname>Beger</surname><given-names>H</given-names></name><name><surname>Dolara</surname><given-names>P</given-names></name><name><surname>Winde</surname><given-names>G</given-names></name><name><surname>Bartsch</surname><given-names>H</given-names></name></person-group><article-title>Increased etheno-DNA adducts in affected tissues of patients suffering from crohn's disease, ulcerative colitis, and chronic pancreatitis</article-title><source>Antioxid. Redox. Signal</source><year>2006</year><volume>8</volume><fpage>1003</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1089/ars.2006.8.1003</pub-id><pub-id pub-id-type="pmid">16771690</pub-id></citation></ref>
<ref id="b68-ijms-11-02715"><label>68.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cerutti</surname><given-names>PA</given-names></name><name><surname>Trump</surname><given-names>BF</given-names></name></person-group><article-title>Inflammation and oxidative stress in carcinogenesis</article-title><source>Cancer Cells</source><year>1991</year><volume>3</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">2025490</pub-id></citation></ref>
<ref id="b69-ijms-11-02715"><label>69.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaulian</surname><given-names>E</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>Ap-1 as a regulator of cell life and death</article-title><source>Nat. Cell Biol</source><year>2002</year><volume>4</volume><fpage>E131</fpage><lpage>E136</lpage><pub-id pub-id-type="doi">10.1038/ncb0502-e131</pub-id><pub-id pub-id-type="pmid">11988758</pub-id></citation></ref>
<ref id="b70-ijms-11-02715"><label>70.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hofseth</surname><given-names>LJ</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Hussain</surname><given-names>SP</given-names></name><name><surname>Espey</surname><given-names>MG</given-names></name><name><surname>Miranda</surname><given-names>KM</given-names></name><name><surname>Araki</surname><given-names>Y</given-names></name><name><surname>Jhappan</surname><given-names>C</given-names></name><name><surname>Higashimoto</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>P</given-names></name><name><surname>Linke</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Nitric oxide-induced cellular stress and p53 activation in chronic inflammation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>143</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1073/pnas.0237083100</pub-id><pub-id pub-id-type="pmid">12518062</pub-id></citation></ref>
<ref id="b71-ijms-11-02715"><label>71.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>L</given-names></name><name><surname>Marino</surname><given-names>J</given-names></name><name><surname>Hussain</surname><given-names>SP</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>You</surname><given-names>S</given-names></name><name><surname>Hofseth</surname><given-names>AB</given-names></name><name><surname>Trivers</surname><given-names>GE</given-names></name><name><surname>Dixon</surname><given-names>DA</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name><name><surname>Hofseth</surname><given-names>LJ</given-names></name></person-group><article-title>Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and e2f1 activation</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>9132</fpage><lpage>9136</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1358</pub-id><pub-id pub-id-type="pmid">16230367</pub-id></citation></ref>
<ref id="b72-ijms-11-02715"><label>72.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wink</surname><given-names>DA</given-names></name><name><surname>Hanbauer</surname><given-names>I</given-names></name><name><surname>Grisham</surname><given-names>MB</given-names></name><name><surname>Laval</surname><given-names>F</given-names></name><name><surname>Nims</surname><given-names>RW</given-names></name><name><surname>Laval</surname><given-names>J</given-names></name><name><surname>Cook</surname><given-names>J</given-names></name><name><surname>Pacelli</surname><given-names>R</given-names></name><name><surname>Liebmann</surname><given-names>J</given-names></name><name><surname>Krishna</surname><given-names>M</given-names></name><etal/></person-group><article-title>Chemical biology of nitric oxide: Regulation and protective and toxic mechanisms</article-title><source>Curr. Top Cell Regul</source><year>1996</year><volume>34</volume><fpage>159</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">8646847</pub-id></citation></ref>
<ref id="b73-ijms-11-02715"><label>73.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>GC</given-names></name><name><surname>Charles</surname><given-names>G</given-names></name></person-group><article-title>Nitric oxide upregulates expression of DNA-pkcs to protect cells from DNA-damaging anti-tumour agents</article-title><source>Nat. Cell Biol</source><year>2000</year><volume>2</volume><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/35014028</pub-id><pub-id pub-id-type="pmid">10854324</pub-id></citation></ref>
<ref id="b74-ijms-11-02715"><label>74.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jablonka</surname><given-names>E</given-names></name><name><surname>Lamb</surname><given-names>MJ</given-names></name></person-group><article-title>The changing concept of epigenetics</article-title><source>Ann. NY Acad. Sci</source><year>2002</year><volume>981</volume><fpage>82</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">12547675</pub-id></citation></ref>
<ref id="b75-ijms-11-02715"><label>75.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>J</given-names></name></person-group><article-title>Overview of mammalian genome special issue on epigenetics</article-title><source>Mamm. Genome</source><year>2009</year><volume>20</volume><fpage>529</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1007/s00335-009-9231-4</pub-id><pub-id pub-id-type="pmid">19862571</pub-id></citation></ref>
<ref id="b76-ijms-11-02715"><label>76.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waddington</surname><given-names>CH</given-names></name></person-group><article-title>The epigenotype</article-title><source>Endeavour</source><year>1942</year><fpage>18</fpage><lpage>20</lpage></citation></ref>
<ref id="b77-ijms-11-02715"><label>77.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>PM</given-names></name><name><surname>Singal</surname><given-names>R</given-names></name></person-group><article-title>DNA methylation and cancer</article-title><source>J. Clin. Oncol</source><year>2004</year><volume>22</volume><fpage>4632</fpage><lpage>4642</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.07.151</pub-id><pub-id pub-id-type="pmid">15542813</pub-id></citation></ref>
<ref id="b78-ijms-11-02715"><label>78.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DeAngelis</surname><given-names>JT</given-names></name><name><surname>Farrington</surname><given-names>WJ</given-names></name><name><surname>Tollefsbol</surname><given-names>TO</given-names></name></person-group><article-title>An overview of epigenetic assays</article-title><source>Mol. Biotechnol</source><year>2008</year><volume>38</volume><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1007/s12033-007-9010-y</pub-id><pub-id pub-id-type="pmid">17943463</pub-id></citation></ref>
<ref id="b79-ijms-11-02715"><label>79.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>S</given-names></name><name><surname>Moley</surname><given-names>KH</given-names></name></person-group><article-title>Gametes and embryo epigenetic reprogramming affect developmental outcome: Implication for assisted reproductive technologies</article-title><source>Pediatr. Res</source><year>2005</year><volume>58</volume><fpage>437</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1203/01.PDR.0000179401.17161.D3</pub-id><pub-id pub-id-type="pmid">16148054</pub-id></citation></ref>
<ref id="b80-ijms-11-02715"><label>80.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>WY</given-names></name><name><surname>Ho</surname><given-names>SM</given-names></name></person-group><article-title>Epigenetic reprogramming and imprinting in origins of disease</article-title><source>Rev. Endocr. Metab. Disord</source><year>2007</year><volume>8</volume><fpage>173</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1007/s11154-007-9042-4</pub-id><pub-id pub-id-type="pmid">17638084</pub-id></citation></ref>
<ref id="b81-ijms-11-02715"><label>81.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Sweatt</surname><given-names>JD</given-names></name></person-group><article-title>Covalent modification of DNA regulates memory formation</article-title><source>Neuron</source><year>2007</year><volume>53</volume><fpage>857</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.02.022</pub-id><pub-id pub-id-type="pmid">17359920</pub-id></citation></ref>
<ref id="b82-ijms-11-02715"><label>82.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matouk</surname><given-names>CC</given-names></name><name><surname>Marsden</surname><given-names>PA</given-names></name></person-group><article-title>Epigenetic regulation of vascular endothelial gene expression</article-title><source>Circ. Res</source><year>2008</year><volume>102</volume><fpage>873</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.171025</pub-id><pub-id pub-id-type="pmid">18436802</pub-id></citation></ref>
<ref id="b83-ijms-11-02715"><label>83.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prokhortchouk</surname><given-names>E</given-names></name><name><surname>Defossez</surname><given-names>PA</given-names></name></person-group><article-title>The cell biology of DNA methylation in mammals</article-title><source>Biochim. Biophys. Acta</source><year>2008</year><volume>1783</volume><fpage>2167</fpage><lpage>2173</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2008.07.015</pub-id><pub-id pub-id-type="pmid">18706939</pub-id></citation></ref>
<ref id="b84-ijms-11-02715"><label>84.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>PJ</given-names></name><name><surname>Peterson</surname><given-names>CL</given-names></name></person-group><article-title>Molecular biology. Chromatin higher order folding--wrapping up transcription</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>1824</fpage><lpage>1827</lpage><pub-id pub-id-type="doi">10.1126/science.1074200</pub-id><pub-id pub-id-type="pmid">12228709</pub-id></citation></ref>
<ref id="b85-ijms-11-02715"><label>85.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carthew</surname><given-names>RW</given-names></name><name><surname>Sontheimer</surname><given-names>EJ</given-names></name></person-group><article-title>Origins and mechanisms of mirnas and sirnas</article-title><source>Cell</source><year>2009</year><volume>136</volume><fpage>642</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.01.035</pub-id><pub-id pub-id-type="pmid">19239886</pub-id></citation></ref>
<ref id="b86-ijms-11-02715"><label>86.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luger</surname><given-names>K</given-names></name><name><surname>Mader</surname><given-names>AW</given-names></name><name><surname>Richmond</surname><given-names>RK</given-names></name><name><surname>Sargent</surname><given-names>DF</given-names></name><name><surname>Richmond</surname><given-names>TJ</given-names></name></person-group><article-title>Crystal structure of the nucleosome core particle at 2.8 a resolution</article-title><source>Nature</source><year>1997</year><volume>389</volume><fpage>251</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1038/38444</pub-id><pub-id pub-id-type="pmid">9305837</pub-id></citation></ref>
<ref id="b87-ijms-11-02715"><label>87.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>JC</given-names></name></person-group><article-title>Conformational dynamics of the chromatin fiber in solution: Determinants, mechanisms, and functions</article-title><source>Ann. Rev. Biophys. Biomol. Struct</source><year>2002</year><volume>31</volume><fpage>361</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1146/annurev.biophys.31.101101.140858</pub-id></citation></ref>
<ref id="b88-ijms-11-02715"><label>88.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jenuwein</surname><given-names>T</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name></person-group><article-title>Translating the histone code</article-title><source>Science</source><year>2001</year><volume>293</volume><fpage>1074</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1126/science.1063127</pub-id><pub-id pub-id-type="pmid">11498575</pub-id></citation></ref>
<ref id="b89-ijms-11-02715"><label>89.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name></person-group><article-title>The cpg island searcher: A new www resource</article-title><source>In Silico Biol</source><year>2003</year><volume>3</volume><fpage>235</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">12954087</pub-id></citation></ref>
<ref id="b90-ijms-11-02715"><label>90.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name></person-group><article-title>Cancer epigenomics: DNA methylomes and histone-modification maps</article-title><source>Nat. Rev. Genet</source><year>2007</year><volume>8</volume><fpage>286</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/nrg2005</pub-id><pub-id pub-id-type="pmid">17339880</pub-id></citation></ref>
<ref id="b91-ijms-11-02715"><label>91.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PA</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><article-title>The fundamental role of epigenetic events in cancer</article-title><source>Nat. Rev. Genet</source><year>2002</year><volume>3</volume><fpage>415</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">12042769</pub-id></citation></ref>
<ref id="b92-ijms-11-02715"><label>92.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klose</surname><given-names>RJ</given-names></name><name><surname>Bird</surname><given-names>AP</given-names></name></person-group><article-title>Genomic DNA methylation: The mark and its mediators</article-title><source>Trends Biochem. Sci</source><year>2006</year><volume>31</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2005.12.008</pub-id><pub-id pub-id-type="pmid">16403636</pub-id></citation></ref>
<ref id="b93-ijms-11-02715"><label>93.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name></person-group><article-title>Comprehensive analysis of cpg islands in human chromosomes 21 and 22</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2002</year><volume>99</volume><fpage>3740</fpage><lpage>3745</lpage><pub-id pub-id-type="doi">10.1073/pnas.052410099</pub-id><pub-id pub-id-type="pmid">11891299</pub-id></citation></ref>
<ref id="b94-ijms-11-02715"><label>94.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Catteau</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>JR</given-names></name></person-group><article-title>Brca1 methylation: A significant role in tumour development?</article-title><source>Semin. Cancer Biol</source><year>2002</year><volume>12</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/S1044-579X(02)00056-1</pub-id><pub-id pub-id-type="pmid">12191635</pub-id></citation></ref>
<ref id="b95-ijms-11-02715"><label>95.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>G</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Aparicio</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name></person-group><article-title>Epigenetics in human disease and prospects for epigenetic therapy</article-title><source>Nature</source><year>2004</year><volume>429</volume><fpage>457</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1038/nature02625</pub-id><pub-id pub-id-type="pmid">15164071</pub-id></citation></ref>
<ref id="b96-ijms-11-02715"><label>96.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leone</surname><given-names>G</given-names></name><name><surname>Teofili</surname><given-names>L</given-names></name><name><surname>Voso</surname><given-names>MT</given-names></name><name><surname>Lubbert</surname><given-names>M</given-names></name></person-group><article-title>DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias</article-title><source>Haematologica</source><year>2002</year><volume>87</volume><fpage>1324</fpage><lpage>1341</lpage><pub-id pub-id-type="pmid">12495905</pub-id></citation></ref>
<ref id="b97-ijms-11-02715"><label>97.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsou</surname><given-names>JA</given-names></name><name><surname>Hagen</surname><given-names>JA</given-names></name><name><surname>Carpenter</surname><given-names>CL</given-names></name><name><surname>Laird-Offringa</surname><given-names>IA</given-names></name></person-group><article-title>DNA methylation analysis: A powerful new tool for lung cancer diagnosis</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>5450</fpage><lpage>5461</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205605</pub-id><pub-id pub-id-type="pmid">12154407</pub-id></citation></ref>
<ref id="b98-ijms-11-02715"><label>98.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Casaccia</surname><given-names>P</given-names></name></person-group><article-title>Epigenetic regulation of oligodendrocyte identity</article-title><source>Trends Neurosci</source><year>2010</year><volume>33</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2010.01.007</pub-id><pub-id pub-id-type="pmid">20227775</pub-id></citation></ref>
<ref id="b99-ijms-11-02715"><label>99.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chuang</surname><given-names>JC</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name></person-group><article-title>Epigenetics and micrornas</article-title><source>Pediatr. Res</source><year>2007</year><volume>61</volume><fpage>24R</fpage><lpage>29R</lpage><pub-id pub-id-type="doi">10.1203/pdr.0b013e3180457684</pub-id><pub-id pub-id-type="pmid">17413852</pub-id></citation></ref>
<ref id="b100-ijms-11-02715"><label>100.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>A</given-names></name></person-group><article-title>Cpg island methylator phenotype in colrectal cancer: A current perspective</article-title><source>Curr Colorect Cancer Rep</source><year>2008</year><fpage>77</fpage><lpage>83</lpage></citation></ref>
<ref id="b101-ijms-11-02715"><label>101.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boland</surname><given-names>R</given-names></name></person-group><article-title>Promoter methylation in the genesis of gastrointestinal cancer</article-title><source>Yonsei Med. J</source><year>2009</year><volume>50</volume><fpage>309</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.3349/ymj.2009.50.3.309</pub-id><pub-id pub-id-type="pmid">19568590</pub-id></citation></ref>
<ref id="b102-ijms-11-02715"><label>102.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><article-title>Cancer genes and the pathways they control</article-title><source>Nat. Med</source><year>2004</year><volume>10</volume><fpage>789</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1038/nm1087</pub-id><pub-id pub-id-type="pmid">15286780</pub-id></citation></ref>
<ref id="b103-ijms-11-02715"><label>103.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bedford</surname><given-names>MT</given-names></name><name><surname>van Helden</surname><given-names>PD</given-names></name></person-group><article-title>Hypomethylation of DNA in pathological conditions of the human prostate</article-title><source>Cancer Res</source><year>1987</year><volume>47</volume><fpage>5274</fpage><lpage>5276</lpage><pub-id pub-id-type="pmid">2443238</pub-id></citation></ref>
<ref id="b104-ijms-11-02715"><label>104.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ehrlich</surname><given-names>M</given-names></name></person-group><article-title>DNA methylation in cancer: Too much, but also too little</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>5400</fpage><lpage>5413</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205651</pub-id><pub-id pub-id-type="pmid">12154403</pub-id></citation></ref>
<ref id="b105-ijms-11-02715"><label>105.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YI</given-names></name><name><surname>Giuliano</surname><given-names>A</given-names></name><name><surname>Hatch</surname><given-names>KD</given-names></name><name><surname>Schneider</surname><given-names>A</given-names></name><name><surname>Nour</surname><given-names>MA</given-names></name><name><surname>Dallal</surname><given-names>GE</given-names></name><name><surname>Selhub</surname><given-names>J</given-names></name><name><surname>Mason</surname><given-names>JB</given-names></name></person-group><article-title>Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma</article-title><source>Cancer</source><year>1994</year><volume>74</volume><fpage>893</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19940801)74:3&lt;893::AID-CNCR2820740316&gt;3.0.CO;2-B</pub-id><pub-id pub-id-type="pmid">8039116</pub-id></citation></ref>
<ref id="b106-ijms-11-02715"><label>106.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Hsieh</surname><given-names>SY</given-names></name><name><surname>Sheen</surname><given-names>IS</given-names></name><name><surname>Lee</surname><given-names>WC</given-names></name><name><surname>Chen</surname><given-names>TC</given-names></name><name><surname>Shyu</surname><given-names>WC</given-names></name><name><surname>Liaw</surname><given-names>YF</given-names></name></person-group><article-title>Genome-wide hypomethylation in hepatocellular carcinogenesis</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>4238</fpage><lpage>4243</lpage><pub-id pub-id-type="pmid">11358850</pub-id></citation></ref>
<ref id="b107-ijms-11-02715"><label>107.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>K</given-names></name><name><surname>Brabender</surname><given-names>J</given-names></name><name><surname>Lord</surname><given-names>RV</given-names></name><name><surname>Groshen</surname><given-names>S</given-names></name><name><surname>Greenwald</surname><given-names>BD</given-names></name><name><surname>Krasna</surname><given-names>MJ</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Fleisher</surname><given-names>AS</given-names></name><name><surname>Abraham</surname><given-names>JM</given-names></name><name><surname>Beer</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Hypermethylated apc DNA in plasma and prognosis of patients with esophageal adenocarcinoma</article-title><source>J. Natl. Cancer Inst</source><year>2000</year><volume>92</volume><fpage>1805</fpage><lpage>1811</lpage><pub-id pub-id-type="doi">10.1093/jnci/92.22.1805</pub-id><pub-id pub-id-type="pmid">11078757</pub-id></citation></ref>
<ref id="b108-ijms-11-02715"><label>108.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harden</surname><given-names>SV</given-names></name><name><surname>Tokumaru</surname><given-names>Y</given-names></name><name><surname>Westra</surname><given-names>WH</given-names></name><name><surname>Goodman</surname><given-names>S</given-names></name><name><surname>Ahrendt</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>SC</given-names></name><name><surname>Sidransky</surname><given-names>D</given-names></name></person-group><article-title>Gene promoter hypermethylation in tumors and lymph nodes of stage i lung cancer patients</article-title><source>Clin. Cancer Res</source><year>2003</year><volume>9</volume><fpage>1370</fpage><lpage>1375</lpage><pub-id pub-id-type="pmid">12684406</pub-id></citation></ref>
<ref id="b109-ijms-11-02715"><label>109.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Virmani</surname><given-names>AK</given-names></name><name><surname>Rathi</surname><given-names>A</given-names></name><name><surname>Sathyanarayana</surname><given-names>UG</given-names></name><name><surname>Padar</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>CX</given-names></name><name><surname>Cunnigham</surname><given-names>HT</given-names></name><name><surname>Farinas</surname><given-names>AJ</given-names></name><name><surname>Milchgrub</surname><given-names>S</given-names></name><name><surname>Euhus</surname><given-names>DM</given-names></name><name><surname>Gilcrease</surname><given-names>M</given-names></name><etal/></person-group><article-title>Aberrant methylation of the adenomatous polyposis coli (apc) gene promoter 1a in breast and lung carcinomas</article-title><source>Clin. Cancer Res</source><year>2001</year><volume>7</volume><fpage>1998</fpage><lpage>2004</lpage><pub-id pub-id-type="pmid">11448917</pub-id></citation></ref>
<ref id="b110-ijms-11-02715"><label>110.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KY</given-names></name><name><surname>Ozcelik</surname><given-names>H</given-names></name><name><surname>Cheung</surname><given-names>AN</given-names></name><name><surname>Ngan</surname><given-names>HY</given-names></name><name><surname>Khoo</surname><given-names>US</given-names></name></person-group><article-title>Epigenetic factors controlling the brca1 and brca2 genes in sporadic ovarian cancer</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>4151</fpage><lpage>4156</lpage><pub-id pub-id-type="pmid">12124354</pub-id></citation></ref>
<ref id="b111-ijms-11-02715"><label>111.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dobrovic</surname><given-names>A</given-names></name><name><surname>Simpfendorfer</surname><given-names>D</given-names></name></person-group><article-title>Methylation of the brca1 gene in sporadic breast cancer</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>3347</fpage><lpage>3350</lpage><pub-id pub-id-type="pmid">9269993</pub-id></citation></ref>
<ref id="b112-ijms-11-02715"><label>112.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Cespedes</surname><given-names>M</given-names></name><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Nawroz-Danish</surname><given-names>H</given-names></name><name><surname>Yoo</surname><given-names>GH</given-names></name><name><surname>Koch</surname><given-names>WM</given-names></name><name><surname>Jen</surname><given-names>J</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Sidransky</surname><given-names>D</given-names></name></person-group><article-title>Gene promoter hypermethylation in tumors and serum of head and neck cancer patients</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>892</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">10706101</pub-id></citation></ref>
<ref id="b113-ijms-11-02715"><label>113.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villuendas</surname><given-names>R</given-names></name></person-group><article-title>Loss of p16/ink4a protein expression in non-hodgkin's lymphomas is a frequent finding associated with tumor progression</article-title><source>Am J Pathol</source><year>1998</year><fpage>887</fpage><lpage>897</lpage></citation></ref>
<ref id="b114-ijms-11-02715"><label>114.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graff</surname><given-names>JR</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Lapidus</surname><given-names>RG</given-names></name><name><surname>Chopra</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Jarrard</surname><given-names>DF</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>Pitha</surname><given-names>PM</given-names></name><name><surname>Davidson</surname><given-names>NE</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><article-title>E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>5195</fpage><lpage>5199</lpage><pub-id pub-id-type="pmid">7585573</pub-id></citation></ref>
<ref id="b115-ijms-11-02715"><label>115.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graff</surname><given-names>JR</given-names></name><name><surname>Greenberg</surname><given-names>VE</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Westra</surname><given-names>WH</given-names></name><name><surname>Boghaert</surname><given-names>ER</given-names></name><name><surname>Ain</surname><given-names>KB</given-names></name><name><surname>Saji</surname><given-names>M</given-names></name><name><surname>Zeiger</surname><given-names>MA</given-names></name><name><surname>Zimmer</surname><given-names>SG</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><article-title>Distinct patterns of e-cadherin cpg island methylation in papillary, follicular, hurthle's cell, and poorly differentiated human thyroid carcinoma</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>2063</fpage><lpage>2066</lpage><pub-id pub-id-type="pmid">9605742</pub-id></citation></ref>
<ref id="b116-ijms-11-02715"><label>116.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waki</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>G</given-names></name><name><surname>Tsuchiya</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Nishizuka</surname><given-names>S</given-names></name><name><surname>Motoyama</surname><given-names>T</given-names></name></person-group><article-title>Promoter methylation status of e-cadherin, hmlh1, and p16 genes in nonneoplastic gastric epithelia</article-title><source>Am. J. Pathol</source><year>2002</year><volume>161</volume><fpage>399</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)64195-8</pub-id><pub-id pub-id-type="pmid">12163364</pub-id></citation></ref>
<ref id="b117-ijms-11-02715"><label>117.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Davidson</surname><given-names>NE</given-names></name></person-group><article-title>DNA methylation in breast cancer</article-title><source>Endocr. Relat. Cancer</source><year>2001</year><volume>8</volume><fpage>115</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1677/erc.0.0080115</pub-id><pub-id pub-id-type="pmid">11446343</pub-id></citation></ref>
<ref id="b118-ijms-11-02715"><label>118.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>LC</given-names></name><name><surname>Chui</surname><given-names>R</given-names></name><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Oh</surname><given-names>BR</given-names></name><name><surname>Au</surname><given-names>HC</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>Frequent methylation of estrogen receptor in prostate cancer: Correlation with tumor progression</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>702</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">10676656</pub-id></citation></ref>
<ref id="b119-ijms-11-02715"><label>119.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WH</given-names></name><name><surname>Morton</surname><given-names>RA</given-names></name><name><surname>Epstein</surname><given-names>JI</given-names></name><name><surname>Brooks</surname><given-names>JD</given-names></name><name><surname>Campbell</surname><given-names>PA</given-names></name><name><surname>Bova</surname><given-names>GS</given-names></name><name><surname>Hsieh</surname><given-names>WS</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>Nelson</surname><given-names>WG</given-names></name></person-group><article-title>Cytidine methylation of regulatory sequences near the pi-class glutathione s-transferase gene accompanies human prostatic carcinogenesis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1994</year><volume>91</volume><fpage>11733</fpage><lpage>11737</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.24.11733</pub-id><pub-id pub-id-type="pmid">7972132</pub-id></citation></ref>
<ref id="b120-ijms-11-02715"><label>120.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veigl</surname><given-names>ML</given-names></name><name><surname>Kasturi</surname><given-names>L</given-names></name><name><surname>Olechnowicz</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>AH</given-names></name><name><surname>Lutterbaugh</surname><given-names>JD</given-names></name><name><surname>Periyasamy</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>GM</given-names></name><name><surname>Drummond</surname><given-names>J</given-names></name><name><surname>Modrich</surname><given-names>PL</given-names></name><name><surname>Sedwick</surname><given-names>WD</given-names></name><etal/></person-group><article-title>Biallelic inactivation of hmlh1 by epigenetic gene silencing, a novel mechanism causing human msi cancers</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1998</year><volume>95</volume><fpage>8698</fpage><lpage>8702</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.15.8698</pub-id><pub-id pub-id-type="pmid">9671741</pub-id></citation></ref>
<ref id="b121-ijms-11-02715"><label>121.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>E</given-names></name></person-group><article-title>Not hmsh2 but hmlh1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability</article-title><source>Int J Oncol</source><year>2000</year><fpage>535</fpage><lpage>541</lpage></citation></ref>
<ref id="b122-ijms-11-02715"><label>122.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strathdee</surname><given-names>G</given-names></name><name><surname>MacKean</surname><given-names>MJ</given-names></name><name><surname>Illand</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name></person-group><article-title>A role for methylation of the hmlh1 promoter in loss of hmlh1 expression and drug resistance in ovarian cancer</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>2335</fpage><lpage>2341</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202540</pub-id><pub-id pub-id-type="pmid">10327053</pub-id></citation></ref>
<ref id="b123-ijms-11-02715"><label>123.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harden</surname><given-names>SV</given-names></name><name><surname>Tokumaru</surname><given-names>Y</given-names></name><name><surname>Westra</surname><given-names>WH</given-names></name><name><surname>Goodman</surname><given-names>S</given-names></name><name><surname>Ahrendt</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>SC</given-names></name><name><surname>Sidransky</surname><given-names>D</given-names></name></person-group><article-title>Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients</article-title><source>Clin. Cancer Res</source><year>2003</year><volume>9</volume><fpage>1370</fpage><lpage>1375</lpage><pub-id pub-id-type="pmid">12684406</pub-id></citation></ref>
<ref id="b124-ijms-11-02715"><label>124.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Garcia-Foncillas</surname><given-names>J</given-names></name><name><surname>Andion</surname><given-names>E</given-names></name><name><surname>Goodman</surname><given-names>SN</given-names></name><name><surname>Hidalgo</surname><given-names>OF</given-names></name><name><surname>Vanaclocha</surname><given-names>V</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name></person-group><article-title>Inactivation of the DNA-repair gene mgmt and the clinical response of gliomas to alkylating agents</article-title><source>N. Engl. J. Med</source><year>2000</year><volume>343</volume><fpage>1350</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1056/NEJM200011093431901</pub-id><pub-id pub-id-type="pmid">11070098</pub-id></citation></ref>
<ref id="b125-ijms-11-02715"><label>125.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melki</surname><given-names>JR</given-names></name><name><surname>Vincent</surname><given-names>PC</given-names></name><name><surname>Clark</surname><given-names>SJ</given-names></name></person-group><article-title>Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>3730</fpage><lpage>3740</lpage><pub-id pub-id-type="pmid">10446989</pub-id></citation></ref>
<ref id="b126-ijms-11-02715"><label>126.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>MJ</given-names></name><name><surname>Martinez-Delgado</surname><given-names>B</given-names></name><name><surname>Cebrian</surname><given-names>A</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Benitez</surname><given-names>J</given-names></name><name><surname>Rivas</surname><given-names>C</given-names></name></person-group><article-title>Different incidence and pattern of p15ink4b and p16ink4a promoter region hypermethylation in hodgkin's and cd30-positive non-hodgkin's lymphomas</article-title><source>Am. J. Pathol</source><year>2002</year><volume>161</volume><fpage>1007</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)64261-7</pub-id><pub-id pub-id-type="pmid">12213729</pub-id></citation></ref>
<ref id="b127-ijms-11-02715"><label>127.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Jen</surname><given-names>J</given-names></name><name><surname>Merlo</surname><given-names>A</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><article-title>Hypermethylation-associated inactivation indicates a tumor suppressor role for p15ink4b</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>722</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">8631003</pub-id></citation></ref>
<ref id="b128-ijms-11-02715"><label>128.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agathanggelou</surname><given-names>A</given-names></name></person-group><article-title>Methylation associated inactivation of rassf1a from region 3p21.3 in lung, breast and ovarian tumours</article-title><source>Oncogene</source><year>2001</year><fpage>1509</fpage><lpage>1518</lpage></citation></ref>
<ref id="b129-ijms-11-02715"><label>129.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morrissey</surname><given-names>C</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Zatyka</surname><given-names>M</given-names></name><name><surname>Agathanggelou</surname><given-names>A</given-names></name><name><surname>Honorio</surname><given-names>S</given-names></name><name><surname>Astuti</surname><given-names>D</given-names></name><name><surname>Morgan</surname><given-names>NV</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Richards</surname><given-names>FM</given-names></name><name><surname>Kishida</surname><given-names>T</given-names></name><etal/></person-group><article-title>Epigenetic inactivation of the rassf1a 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>7277</fpage><lpage>7281</lpage><pub-id pub-id-type="pmid">11585766</pub-id></citation></ref>
<ref id="b130-ijms-11-02715"><label>130.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>J</given-names></name><name><surname>Lo</surname><given-names>KW</given-names></name><name><surname>To</surname><given-names>KF</given-names></name><name><surname>Teo</surname><given-names>PM</given-names></name><name><surname>Johnson</surname><given-names>PJ</given-names></name><name><surname>Huang</surname><given-names>DP</given-names></name></person-group><article-title>Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma</article-title><source>Clin. Cancer Res</source><year>2002</year><volume>8</volume><fpage>131</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">11801549</pub-id></citation></ref>
<ref id="b131-ijms-11-02715"><label>131.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stirzaker</surname><given-names>C</given-names></name><name><surname>Millar</surname><given-names>DS</given-names></name><name><surname>Paul</surname><given-names>CL</given-names></name><name><surname>Warnecke</surname><given-names>PM</given-names></name><name><surname>Harrison</surname><given-names>J</given-names></name><name><surname>Vincent</surname><given-names>PC</given-names></name><name><surname>Frommer</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>SJ</given-names></name></person-group><article-title>Extensive DNA methylation spanning the rb promoter in retinoblastoma tumors</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>2229</fpage><lpage>2237</lpage><pub-id pub-id-type="pmid">9187126</pub-id></citation></ref>
<ref id="b132-ijms-11-02715"><label>132.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Gomez</surname><given-names>P</given-names></name><name><surname>Bello</surname><given-names>MJ</given-names></name><name><surname>Alonso</surname><given-names>ME</given-names></name><name><surname>Arjona</surname><given-names>D</given-names></name><name><surname>Lomas</surname><given-names>J</given-names></name><name><surname>de Campos</surname><given-names>JM</given-names></name><name><surname>Isla</surname><given-names>A</given-names></name><name><surname>Rey</surname><given-names>JA</given-names></name></person-group><article-title>Cpg island methylation status and mutation analysis of the rb1 gene essential promoter region and protein-binding pocket domain in nervous system tumours</article-title><source>Br. J. Cancer</source><year>2003</year><volume>88</volume><fpage>109</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600737</pub-id><pub-id pub-id-type="pmid">12556968</pub-id></citation></ref>
<ref id="b133-ijms-11-02715"><label>133.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tannenbaum</surname><given-names>SR</given-names></name><name><surname>White</surname><given-names>FM</given-names></name></person-group><article-title>Regulation and specificity of s-nitrosylation and denitrosylation</article-title><source>ACS Chem. Biol</source><year>2006</year><volume>1</volume><fpage>615</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1021/cb600439h</pub-id><pub-id pub-id-type="pmid">17168564</pub-id></citation></ref>
<ref id="b134-ijms-11-02715"><label>134.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sbaa</surname><given-names>E</given-names></name><name><surname>Frerart</surname><given-names>F</given-names></name><name><surname>Feron</surname><given-names>O</given-names></name></person-group><article-title>The double regulation of endothelial nitric oxide synthase by caveolae and caveolin: A paradox solved through the study of angiogenesis</article-title><source>Trends Cardiovasc. Med</source><year>2005</year><volume>15</volume><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2005.05.006</pub-id><pub-id pub-id-type="pmid">16165011</pub-id></citation></ref>
<ref id="b135-ijms-11-02715"><label>135.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Minchenkova</surname><given-names>LE</given-names></name><name><surname>Ivanov</surname><given-names>VI</given-names></name></person-group><article-title>Influence of reductants upon optical characteristics of the DNA-Cu<sup>2+</sup> complex</article-title><source>Biopolymers</source><year>1967</year><volume>5</volume><fpage>615</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1002/bip.1967.360050703</pub-id><pub-id pub-id-type="pmid">6074259</pub-id></citation></ref>
<ref id="b136-ijms-11-02715"><label>136.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>E</given-names></name><name><surname>Fant</surname><given-names>J</given-names></name><name><surname>Norton</surname><given-names>W</given-names></name></person-group><article-title>Intracellular iron-binding macromolecules in hela cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1972</year><volume>69</volume><fpage>3708</fpage><lpage>3712</lpage><pub-id pub-id-type="doi">10.1073/pnas.69.12.3708</pub-id><pub-id pub-id-type="pmid">4509333</pub-id></citation></ref>
<ref id="b137-ijms-11-02715"><label>137.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bitny-Szlachto</surname><given-names>S</given-names></name><name><surname>Ochalska-Czepulis</surname><given-names>M</given-names></name></person-group><article-title>Effects of disulphides and alpha-oxoglutarate on nuclear thiol formation and thiol content of chromatin in lysed rat spleen nuclei</article-title><source>Int. J. Biochem</source><year>1978</year><volume>9</volume><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/0020-711X(78)90147-7</pub-id><pub-id pub-id-type="pmid">648701</pub-id></citation></ref>
<ref id="b138-ijms-11-02715"><label>138.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanin</surname><given-names>AF</given-names></name><name><surname>Ivanov</surname><given-names>VI</given-names></name></person-group><article-title>Interaction of iron ions with oxygen or nitrogen monoxide in chromosomes triggers synchronous expression/suppression oscillations of compact gene groups (“Genomewide oscillation”): Hypothesis</article-title><source>Nitric Oxide</source><year>2008</year><volume>18</volume><fpage>147</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.niox.2008.01.007</pub-id><pub-id pub-id-type="pmid">18291123</pub-id></citation></ref>
<ref id="b139-ijms-11-02715"><label>139.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elzaouk</surname><given-names>L</given-names></name><name><surname>Laufs</surname><given-names>S</given-names></name><name><surname>Heerklotz</surname><given-names>D</given-names></name><name><surname>Leimbacher</surname><given-names>W</given-names></name><name><surname>Blau</surname><given-names>N</given-names></name><name><surname>Resibois</surname><given-names>A</given-names></name><name><surname>Thony</surname><given-names>B</given-names></name></person-group><article-title>Nuclear localization of tetrahydrobiopterin biosynthetic enzymes</article-title><source>Biochim. Biophys. Acta</source><year>2004</year><volume>1670</volume><fpage>56</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2003.10.015</pub-id><pub-id pub-id-type="pmid">14729142</pub-id></citation></ref>
<ref id="b140-ijms-11-02715"><label>140.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>Microrna signatures in human cancers</article-title><source>Nat. Rev. Cancer</source><year>2006</year><volume>6</volume><fpage>857</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1038/nrc1997</pub-id><pub-id pub-id-type="pmid">17060945</pub-id></citation></ref>
<ref id="b141-ijms-11-02715"><label>141.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nilsen</surname><given-names>TW</given-names></name></person-group><article-title>Mechanisms of microrna-mediated gene regulation in animal cells</article-title><source>Trends Genet</source><year>2007</year><volume>23</volume><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2007.02.011</pub-id><pub-id pub-id-type="pmid">17368621</pub-id></citation></ref>
<ref id="b142-ijms-11-02715"><label>142.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farh</surname><given-names>KK</given-names></name><name><surname>Grimson</surname><given-names>A</given-names></name><name><surname>Jan</surname><given-names>C</given-names></name><name><surname>Lewis</surname><given-names>BP</given-names></name><name><surname>Johnston</surname><given-names>WK</given-names></name><name><surname>Lim</surname><given-names>LP</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>The widespread impact of mammalian micrornas on mrna repression and evolution</article-title><source>Science</source><year>2005</year><volume>310</volume><fpage>1817</fpage><lpage>1821</lpage><pub-id pub-id-type="doi">10.1126/science.1121158</pub-id><pub-id pub-id-type="pmid">16308420</pub-id></citation></ref>
<ref id="b143-ijms-11-02715"><label>143.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>BP</given-names></name><name><surname>Shih</surname><given-names>IH</given-names></name><name><surname>Jones-Rhoades</surname><given-names>MW</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name></person-group><article-title>Prediction of mammalian microrna targets</article-title><source>Cell</source><year>2003</year><volume>115</volume><fpage>787</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(03)01018-3</pub-id><pub-id pub-id-type="pmid">14697198</pub-id></citation></ref>
<ref id="b144-ijms-11-02715"><label>144.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>A</given-names></name><name><surname>Brennecke</surname><given-names>J</given-names></name><name><surname>Bushati</surname><given-names>N</given-names></name><name><surname>Russell</surname><given-names>RB</given-names></name><name><surname>Cohen</surname><given-names>SM</given-names></name></person-group><article-title>Animal micrornas confer robustness to gene expression and have a significant impact on 3'utr evolution</article-title><source>Cell</source><year>2005</year><volume>123</volume><fpage>1133</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.11.023</pub-id><pub-id pub-id-type="pmid">16337999</pub-id></citation></ref>
<ref id="b145-ijms-11-02715"><label>145.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dews</surname><given-names>M</given-names></name><name><surname>Homayouni</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>D</given-names></name><name><surname>Sevignani</surname><given-names>C</given-names></name><name><surname>Wentzel</surname><given-names>E</given-names></name><name><surname>Furth</surname><given-names>EE</given-names></name><name><surname>Lee</surname><given-names>WM</given-names></name><name><surname>Enders</surname><given-names>GH</given-names></name><name><surname>Mendell</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Augmentation of tumor angiogenesis by a myc-activated microrna cluster</article-title><source>Nat. Genet</source><year>2006</year><volume>38</volume><fpage>1060</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1038/ng1855</pub-id><pub-id pub-id-type="pmid">16878133</pub-id></citation></ref>
<ref id="b146-ijms-11-02715"><label>146.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>KA</given-names></name><name><surname>Wentzel</surname><given-names>EA</given-names></name><name><surname>Zeller</surname><given-names>KI</given-names></name><name><surname>Dang</surname><given-names>CV</given-names></name><name><surname>Mendell</surname><given-names>JT</given-names></name></person-group><article-title>C-myc-regulated micrornas modulate e2f1 expression</article-title><source>Nature</source><year>2005</year><volume>435</volume><fpage>839</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1038/nature03677</pub-id><pub-id pub-id-type="pmid">15944709</pub-id></citation></ref>
<ref id="b147-ijms-11-02715"><label>147.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayashita</surname><given-names>Y</given-names></name><name><surname>Osada</surname><given-names>H</given-names></name><name><surname>Tatematsu</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Yanagisawa</surname><given-names>K</given-names></name><name><surname>Tomida</surname><given-names>S</given-names></name><name><surname>Yatabe</surname><given-names>Y</given-names></name><name><surname>Kawahara</surname><given-names>K</given-names></name><name><surname>Sekido</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name></person-group><article-title>A polycistronic microrna cluster, mir-17-92, is overexpressed in human lung cancers and enhances cell proliferation</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>9628</fpage><lpage>9632</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2352</pub-id><pub-id pub-id-type="pmid">16266980</pub-id></citation></ref>
<ref id="b148-ijms-11-02715"><label>148.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L</given-names></name><name><surname>Thomson</surname><given-names>JM</given-names></name><name><surname>Hemann</surname><given-names>MT</given-names></name><name><surname>Hernando-Monge</surname><given-names>E</given-names></name><name><surname>Mu</surname><given-names>D</given-names></name><name><surname>Goodson</surname><given-names>S</given-names></name><name><surname>Powers</surname><given-names>S</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>A microrna polycistron as a potential human oncogene</article-title><source>Nature</source><year>2005</year><volume>435</volume><fpage>828</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1038/nature03552</pub-id><pub-id pub-id-type="pmid">15944707</pub-id></citation></ref>
<ref id="b149-ijms-11-02715"><label>149.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Miska</surname><given-names>EA</given-names></name><name><surname>Alvarez-Saavedra</surname><given-names>E</given-names></name><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Peck</surname><given-names>D</given-names></name><name><surname>Sweet-Cordero</surname><given-names>A</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Mak</surname><given-names>RH</given-names></name><name><surname>Ferrando</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Microrna expression profiles classify human cancers</article-title><source>Nature</source><year>2005</year><volume>435</volume><fpage>834</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/nature03702</pub-id><pub-id pub-id-type="pmid">15944708</pub-id></citation></ref>
<ref id="b150-ijms-11-02715"><label>150.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benetti</surname><given-names>R</given-names></name><name><surname>Gonzalo</surname><given-names>S</given-names></name><name><surname>Jaco</surname><given-names>I</given-names></name><name><surname>Munoz</surname><given-names>P</given-names></name><name><surname>Gonzalez</surname><given-names>S</given-names></name><name><surname>Schoeftner</surname><given-names>S</given-names></name><name><surname>Murchison</surname><given-names>E</given-names></name><name><surname>Andl</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Klatt</surname><given-names>P</given-names></name><etal/></person-group><article-title>A mammalian microrna cluster controls DNA methylation and telomere recombination via rbl2-dependent regulation of DNA methyltransferases</article-title><source>Nat. Struct. Mol. Biol</source><year>2008</year><volume>15</volume><fpage>268</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1399</pub-id><pub-id pub-id-type="pmid">18311151</pub-id></citation></ref>
<ref id="b151-ijms-11-02715"><label>151.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sinkkonen</surname><given-names>L</given-names></name><name><surname>Hugenschmidt</surname><given-names>T</given-names></name><name><surname>Berninger</surname><given-names>P</given-names></name><name><surname>Gaidatzis</surname><given-names>D</given-names></name><name><surname>Mohn</surname><given-names>F</given-names></name><name><surname>Artus-Revel</surname><given-names>CG</given-names></name><name><surname>Zavolan</surname><given-names>M</given-names></name><name><surname>Svoboda</surname><given-names>P</given-names></name><name><surname>Filipowicz</surname><given-names>W</given-names></name></person-group><article-title>Micrornas control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells</article-title><source>Nat. Struct. Mol. Biol</source><year>2008</year><volume>15</volume><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1391</pub-id><pub-id pub-id-type="pmid">18311153</pub-id></citation></ref>
<ref id="b152-ijms-11-02715"><label>152.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JA</given-names></name><name><surname>Krichevsky</surname><given-names>AM</given-names></name><name><surname>Kosik</surname><given-names>KS</given-names></name></person-group><article-title>Microrna-21 is an antiapoptotic factor in human glioblastoma cells</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>6029</fpage><lpage>6033</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0137</pub-id><pub-id pub-id-type="pmid">16024602</pub-id></citation></ref>
<ref id="b153-ijms-11-02715"><label>153.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>RK</given-names></name><name><surname>Bentz</surname><given-names>BG</given-names></name><name><surname>Haines</surname><given-names>GK</given-names><suffix>III</suffix></name><name><surname>Robinson</surname><given-names>AM</given-names></name><name><surname>Radosevich</surname><given-names>JA</given-names></name></person-group><article-title>Expression of glutathione s-transferase pi in benign mucosa, barrett's metaplasia, and adenocarcinoma of the esophagus</article-title><source>Head Neck</source><year>2002</year><volume>24</volume><fpage>575</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1002/hed.10093</pub-id><pub-id pub-id-type="pmid">12112555</pub-id></citation></ref>
<ref id="b154-ijms-11-02715"><label>154.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Voorhoeve</surname><given-names>PM</given-names></name><name><surname>le Sage</surname><given-names>C</given-names></name><name><surname>Schrier</surname><given-names>M</given-names></name><name><surname>Gillis</surname><given-names>AJ</given-names></name><name><surname>Stoop</surname><given-names>H</given-names></name><name><surname>Nagel</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>YP</given-names></name><name><surname>van Duijse</surname><given-names>J</given-names></name><name><surname>Drost</surname><given-names>J</given-names></name><name><surname>Griekspoor</surname><given-names>A</given-names></name><etal/></person-group><article-title>A genetic screen implicates mirna-372 and mirna-373 as oncogenes in testicular germ cell tumors</article-title><source>Cell</source><year>2006</year><volume>124</volume><fpage>1169</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.02.037</pub-id><pub-id pub-id-type="pmid">16564011</pub-id></citation></ref>
<ref id="b155-ijms-11-02715"><label>155.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eis</surname><given-names>PS</given-names></name><name><surname>Tam</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Chadburn</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Gomez</surname><given-names>MF</given-names></name><name><surname>Lund</surname><given-names>E</given-names></name><name><surname>Dahlberg</surname><given-names>JE</given-names></name></person-group><article-title>Accumulation of mir-155 and bic rna in human b cell lymphomas</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>3627</fpage><lpage>3632</lpage><pub-id pub-id-type="doi">10.1073/pnas.0500613102</pub-id><pub-id pub-id-type="pmid">15738415</pub-id></citation></ref>
<ref id="b156-ijms-11-02715"><label>156.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname><given-names>MV</given-names></name><name><surname>Ferracin</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>CG</given-names></name><name><surname>Veronese</surname><given-names>A</given-names></name><name><surname>Spizzo</surname><given-names>R</given-names></name><name><surname>Sabbioni</surname><given-names>S</given-names></name><name><surname>Magri</surname><given-names>E</given-names></name><name><surname>Pedriali</surname><given-names>M</given-names></name><name><surname>Fabbri</surname><given-names>M</given-names></name><name><surname>Campiglio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Microrna gene expression deregulation in human breast cancer</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>7065</fpage><lpage>7070</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1783</pub-id><pub-id pub-id-type="pmid">16103053</pub-id></citation></ref>
<ref id="b157-ijms-11-02715"><label>157.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tam</surname><given-names>W</given-names></name><name><surname>Dahlberg</surname><given-names>JE</given-names></name></person-group><article-title>Mir-155/bic as an oncogenic microrna</article-title><source>Genes Chromos. Cancer</source><year>2006</year><volume>45</volume><fpage>211</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1002/gcc.20282</pub-id><pub-id pub-id-type="pmid">16252262</pub-id></citation></ref>
<ref id="b158-ijms-11-02715"><label>158.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Egger</surname><given-names>G</given-names></name><name><surname>Friedman</surname><given-names>JM</given-names></name><name><surname>Chuang</surname><given-names>JC</given-names></name><name><surname>Coetzee</surname><given-names>GA</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name></person-group><article-title>Specific activation of microrna-127 with downregulation of the proto-oncogene bcl6 by chromatin-modifying drugs in human cancer cells</article-title><source>Cancer Cell</source><year>2006</year><volume>9</volume><fpage>435</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.04.020</pub-id><pub-id pub-id-type="pmid">16766263</pub-id></citation></ref>
<ref id="b159-ijms-11-02715"><label>159.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>CB</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name></person-group><article-title>Epigenetic therapy of cancer: Past, present and future</article-title><source>Nat. Rev. Drug Discov</source><year>2006</year><volume>5</volume><fpage>37</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/nrd1930</pub-id><pub-id pub-id-type="pmid">16485345</pub-id></citation></ref>
<ref id="b160-ijms-11-02715"><label>160.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>MB</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Searles</surname><given-names>CD</given-names></name></person-group><article-title>Mir-21 is induced in endothelial cells by shear stress and modulates apoptosis and enos activity</article-title><source>Biochem. Biophys. Res. Commun</source><year>2010</year><volume>393</volume><fpage>643</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.02.045</pub-id><pub-id pub-id-type="pmid">20153722</pub-id></citation></ref>
<ref id="b161-ijms-11-02715"><label>161.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Yue</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Dean</surname><given-names>DB</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>Microrna expression signature and antisense-mediated depletion reveal an essential role of microrna in vascular neointimal lesion formation</article-title><source>Circ. Res</source><year>2007</year><volume>100</volume><fpage>1579</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.106.141986</pub-id><pub-id pub-id-type="pmid">17478730</pub-id></citation></ref>
<ref id="b162-ijms-11-02715"><label>162.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tatsuguchi</surname><given-names>M</given-names></name><name><surname>Seok</surname><given-names>HY</given-names></name><name><surname>Callis</surname><given-names>TE</given-names></name><name><surname>Thomson</surname><given-names>JM</given-names></name><name><surname>Chen</surname><given-names>JF</given-names></name><name><surname>Newman</surname><given-names>M</given-names></name><name><surname>Rojas</surname><given-names>M</given-names></name><name><surname>Hammond</surname><given-names>SM</given-names></name><name><surname>Wang</surname><given-names>DZ</given-names></name></person-group><article-title>Expression of micrornas is dynamically regulated during cardiomyocyte hypertrophy</article-title><source>J. Mol. Cell Cardiol</source><year>2007</year><volume>42</volume><fpage>1137</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2007.04.004</pub-id><pub-id pub-id-type="pmid">17498736</pub-id></citation></ref>
<ref id="b163-ijms-11-02715"><label>163.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>CG</given-names></name></person-group><article-title>Microrna and cancer--focus on apoptosis</article-title><source>J. Cell Mol. Med</source><year>2009</year><volume>13</volume><fpage>12</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">19175697</pub-id></citation></ref>
<ref id="b164-ijms-11-02715"><label>164.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Carter</surname><given-names>AD</given-names></name><name><surname>Childs</surname><given-names>SJ</given-names></name></person-group><article-title>Mir-145 directs intestinal maturation in zebrafish</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>17793</fpage><lpage>17798</lpage><pub-id pub-id-type="doi">10.1073/pnas.0903693106</pub-id><pub-id pub-id-type="pmid">19805048</pub-id></citation></ref>
<ref id="b165-ijms-11-02715"><label>165.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Matta</surname><given-names>R</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>CG</given-names></name><name><surname>Nelin</surname><given-names>LD</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Inducible nitric-oxide synthase expression is regulated by mitogen-activated protein kinase phosphatase-1</article-title><source>J. Biol. Chem</source><year>2009</year><volume>284</volume><fpage>27123</fpage><lpage>27134</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.051235</pub-id><pub-id pub-id-type="pmid">19651781</pub-id></citation></ref>
<ref id="b166-ijms-11-02715"><label>166.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bui-Nguyen</surname><given-names>TM</given-names></name><name><surname>Pakala</surname><given-names>SB</given-names></name><name><surname>Sirigiri</surname><given-names>DR</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Murad</surname><given-names>F</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name></person-group><article-title>Stimulation of inducible nitric oxide by hepatitis b virus transactivator protein hbx requires mta1 coregulator</article-title><source>J. Biol. Chem</source><year>2010</year><volume>285</volume><fpage>6980</fpage><lpage>6986</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.065987</pub-id><pub-id pub-id-type="pmid">20022949</pub-id></citation></ref>
<ref id="b167-ijms-11-02715"><label>167.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Meissner</surname><given-names>A</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name></person-group><article-title>The mammalian epigenome</article-title><source>Cell</source><year>2007</year><volume>128</volume><fpage>669</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.01.033</pub-id><pub-id pub-id-type="pmid">17320505</pub-id></citation></ref>
<ref id="b168-ijms-11-02715"><label>168.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>GC</given-names></name><name><surname>Fish</surname><given-names>JE</given-names></name><name><surname>Mawji</surname><given-names>IA</given-names></name><name><surname>Leung</surname><given-names>DD</given-names></name><name><surname>Rachlis</surname><given-names>AC</given-names></name><name><surname>Marsden</surname><given-names>PA</given-names></name></person-group><article-title>Epigenetic basis for the transcriptional hyporesponsiveness of the human inducible nitric oxide synthase gene in vascular endothelial cells</article-title><source>J. Immunol</source><year>2005</year><volume>175</volume><fpage>3846</fpage><lpage>3861</lpage><pub-id pub-id-type="pmid">16148131</pub-id></citation></ref>
<ref id="b169-ijms-11-02715"><label>169.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>AD</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name><name><surname>Bernstein</surname><given-names>E</given-names></name></person-group><article-title>Epigenetics: A landscape takes shape</article-title><source>Cell</source><year>2007</year><volume>128</volume><fpage>635</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.02.006</pub-id><pub-id pub-id-type="pmid">17320500</pub-id></citation></ref>
<ref id="b170-ijms-11-02715"><label>170.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><article-title>Chromatin modifications and their function</article-title><source>Cell</source><year>2007</year><volume>128</volume><fpage>693</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.02.005</pub-id><pub-id pub-id-type="pmid">17320507</pub-id></citation></ref>
<ref id="b171-ijms-11-02715"><label>171.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allis</surname><given-names>CD</given-names></name><name><surname>Berger</surname><given-names>SL</given-names></name><name><surname>Cote</surname><given-names>J</given-names></name><name><surname>Dent</surname><given-names>S</given-names></name><name><surname>Jenuwien</surname><given-names>T</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name><name><surname>Pillus</surname><given-names>L</given-names></name><name><surname>Reinberg</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Shiekhattar</surname><given-names>R</given-names></name><etal/></person-group><article-title>New nomenclature for chromatin-modifying enzymes</article-title><source>Cell</source><year>2007</year><volume>131</volume><fpage>633</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.10.039</pub-id><pub-id pub-id-type="pmid">18022353</pub-id></citation></ref>
<ref id="b172-ijms-11-02715"><label>172.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XJ</given-names></name><name><surname>Seto</surname><given-names>E</given-names></name></person-group><article-title>The rpd3/hda1 family of lysine deacetylases: From bacteria and yeast to mice and men</article-title><source>Nat. Rev. Mol. Cell Biol</source><year>2008</year><volume>9</volume><fpage>206</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nrm2346</pub-id><pub-id pub-id-type="pmid">18292778</pub-id></citation></ref>
<ref id="b173-ijms-11-02715"><label>173.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>BC</given-names></name><name><surname>Hallows</surname><given-names>WC</given-names></name><name><surname>Denu</surname><given-names>JM</given-names></name></person-group><article-title>Mechanisms and molecular probes of sirtuins</article-title><source>Chem. Biol</source><year>2008</year><volume>15</volume><fpage>1002</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2008.09.009</pub-id><pub-id pub-id-type="pmid">18940661</pub-id></citation></ref>
<ref id="b174-ijms-11-02715"><label>174.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GG</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name><name><surname>Chi</surname><given-names>P</given-names></name></person-group><article-title>Chromatin remodeling and cancer, part I: Covalent histone modifications</article-title><source>Trends Mol. Med</source><year>2007</year><volume>13</volume><fpage>363</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2007.07.003</pub-id><pub-id pub-id-type="pmid">17822958</pub-id></citation></ref>
<ref id="b175-ijms-11-02715"><label>175.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>N</given-names></name><name><surname>Seto</surname><given-names>E</given-names></name></person-group><article-title>Regulation of histone deacetylase activities</article-title><source>J. Cell Biochem</source><year>2004</year><volume>93</volume><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1002/jcb.20179</pub-id><pub-id pub-id-type="pmid">15352162</pub-id></citation></ref>
<ref id="b176-ijms-11-02715"><label>176.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stamler</surname><given-names>JS</given-names></name><name><surname>Singel</surname><given-names>DJ</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name></person-group><article-title>Biochemistry of nitric oxide and its redox-activated forms</article-title><source>Science</source><year>1992</year><volume>258</volume><fpage>1898</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1126/science.1281928</pub-id><pub-id pub-id-type="pmid">1281928</pub-id></citation></ref>
<ref id="b177-ijms-11-02715"><label>177.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XJ</given-names></name><name><surname>Gregoire</surname><given-names>S</given-names></name></person-group><article-title>Class ii histone deacetylases: From sequence to function, regulation, and clinical implication</article-title><source>Mol. Cell Biol</source><year>2005</year><volume>25</volume><fpage>2873</fpage><lpage>2884</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.8.2873-2884.2005</pub-id><pub-id pub-id-type="pmid">15798178</pub-id></citation></ref>
<ref id="b178-ijms-11-02715"><label>178.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Handschin</surname><given-names>C</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>Metabolic control through the pgc-1 family of transcription coactivators</article-title><source>Cell Metab</source><year>2005</year><volume>1</volume><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2005.05.004</pub-id><pub-id pub-id-type="pmid">16054085</pub-id></citation></ref>
<ref id="b179-ijms-11-02715"><label>179.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fraga</surname><given-names>MF</given-names></name><name><surname>Esteller</surname><given-names>M</given-names></name></person-group><article-title>DNA methylation: A profile of methods and applications</article-title><source>BioTechniques</source><year>2002</year><volume>33</volume><fpage>632</fpage><fpage>634</fpage><fpage>636</fpage><lpage>649</lpage></citation></ref>
<ref id="b180-ijms-11-02715"><label>180.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singal</surname><given-names>R</given-names></name><name><surname>Ginder</surname><given-names>GD</given-names></name></person-group><article-title>DNA methylation</article-title><source>Blood</source><year>1999</year><volume>93</volume><fpage>4059</fpage><lpage>4070</lpage><pub-id pub-id-type="pmid">10361102</pub-id></citation></ref>
<ref id="b181-ijms-11-02715"><label>181.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nestor</surname><given-names>C</given-names></name></person-group><article-title>Enzymatic approaches and bisulfite sequencing cannot distinguish between 5-methylcytosine and 5-hydroxymethylcytosine in DNA</article-title><source>BioTechniques</source><year>2010</year><volume>48</volume><fpage>317</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.2144/000113403</pub-id><pub-id pub-id-type="pmid">20569209</pub-id></citation></ref>
<ref id="b182-ijms-11-02715"><label>182.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>Y</given-names></name><name><surname>Fish</surname><given-names>JE</given-names></name><name><surname>D'Abreo</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Robb</surname><given-names>GB</given-names></name><name><surname>Teichert</surname><given-names>AM</given-names></name><name><surname>Karantzoulis-Fegaras</surname><given-names>F</given-names></name><name><surname>Keightley</surname><given-names>A</given-names></name><name><surname>Steer</surname><given-names>BM</given-names></name><name><surname>Marsden</surname><given-names>PA</given-names></name></person-group><article-title>The cell-specific expression of endothelial nitric-oxide synthase: A role for DNA methylation</article-title><source>J. Biol. Chem</source><year>2004</year><volume>279</volume><fpage>35087</fpage><lpage>35100</lpage><pub-id pub-id-type="doi">10.1074/jbc.M405063200</pub-id><pub-id pub-id-type="pmid">15180995</pub-id></citation></ref>
<ref id="b183-ijms-11-02715"><label>183.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guillot</surname><given-names>PV</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Kuivenhoven</surname><given-names>JA</given-names></name><name><surname>Guan</surname><given-names>J</given-names></name><name><surname>Rosenberg</surname><given-names>RD</given-names></name><name><surname>Aird</surname><given-names>WC</given-names></name></person-group><article-title>Targeting of human enos promoter to the hprt locus of mice leads to tissue-restricted transgene expression</article-title><source>Physiol. Genomics</source><year>2000</year><volume>2</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">11015585</pub-id></citation></ref>
<ref id="b184-ijms-11-02715"><label>184.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teichert</surname><given-names>AM</given-names></name><name><surname>Miller</surname><given-names>TL</given-names></name><name><surname>Tai</surname><given-names>SC</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Bei</surname><given-names>X</given-names></name><name><surname>Robb</surname><given-names>GB</given-names></name><name><surname>Phillips</surname><given-names>MJ</given-names></name><name><surname>Marsden</surname><given-names>PA</given-names></name></person-group><article-title><italic>In vivo</italic> expression profile of an endothelial nitric oxide synthase promoter-reporter transgene</article-title><source>Am. J. Physiol. Heart Circ. Physiol</source><year>2000</year><volume>278</volume><fpage>H1352</fpage><lpage>1361</lpage><pub-id pub-id-type="pmid">10749733</pub-id></citation></ref>
<ref id="b185-ijms-11-02715"><label>185.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bentz</surname><given-names>BG</given-names></name><name><surname>Hammer</surname><given-names>ND</given-names></name><name><surname>Radosevich</surname><given-names>JA</given-names></name><name><surname>Haines</surname><given-names>GK</given-names><suffix>III</suffix></name></person-group><article-title>Nitrosative stress induces DNA strand breaks but not caspase mediated apoptosis in a lung cancer cell line</article-title><source>J. Carcinog</source><year>2004</year><volume>3</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1186/1477-3163-3-16</pub-id><pub-id pub-id-type="pmid">15617570</pub-id></citation></ref>
<ref id="b186-ijms-11-02715"><label>186.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Radosevich</surname><given-names>JA</given-names></name><name><surname>Elseth</surname><given-names>KM</given-names></name><name><surname>Vesper</surname><given-names>BJ</given-names></name><name><surname>Tarjan</surname><given-names>G</given-names></name><name><surname>Haines</surname><given-names>GK</given-names><suffix>III</suffix></name></person-group><article-title>Long-term adaptation of lung tumor cell lines with increasing concentrations of nitric oxide donor</article-title><source>Open Lung Cancer J</source><year>2009</year><volume>2</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.2174/1876819900902010035</pub-id></citation></ref>
<ref id="b187-ijms-11-02715"><label>187.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vesper</surname><given-names>BJ</given-names></name><name><surname>Elseth</surname><given-names>KM</given-names></name><name><surname>Tarjan</surname><given-names>G</given-names></name><name><surname>Haines</surname><given-names>GK</given-names><suffix>III</suffix></name><name><surname>Radosevich</surname><given-names>JA</given-names></name></person-group><article-title>Long-term adaptation of breast tumor cell lines to high concentrations of nitric oxide</article-title><source>Tumor. Biol</source><year>2010</year><volume>31</volume><fpage>267</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1007/s13277-010-0028-6</pub-id></citation></ref>
<ref id="b188-ijms-11-02715"><label>188.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridnour</surname><given-names>LA</given-names></name><name><surname>Thomas</surname><given-names>DD</given-names></name><name><surname>Donzelli</surname><given-names>S</given-names></name><name><surname>Espey</surname><given-names>MG</given-names></name><name><surname>Roberts</surname><given-names>DD</given-names></name><name><surname>Wink</surname><given-names>DA</given-names></name><name><surname>Isenberg</surname><given-names>JS</given-names></name></person-group><article-title>The biphasic nature of nitric oxide responses in tumor biology</article-title><source>Antioxid. Redox. Signal</source><year>2006</year><volume>8</volume><fpage>1329</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1089/ars.2006.8.1329</pub-id><pub-id pub-id-type="pmid">16910780</pub-id></citation></ref>
<ref id="b189-ijms-11-02715"><label>189.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wink</surname><given-names>DA</given-names></name><name><surname>Mitchell</surname><given-names>JB</given-names></name></person-group><article-title>Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide</article-title><source>Free Radic. Biol. Med</source><year>1998</year><volume>25</volume><fpage>434</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1016/S0891-5849(98)00092-6</pub-id><pub-id pub-id-type="pmid">9741580</pub-id></citation></ref>
<ref id="b190-ijms-11-02715"><label>190.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schetter</surname><given-names>AJ</given-names></name><name><surname>Heegaard</surname><given-names>NH</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name></person-group><article-title>Inflammation and cancer: Interweaving microrna, free radical, cytokine and p53 pathways</article-title><source>Carcinogenesis</source><year>2010</year><volume>31</volume><fpage>37</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgp272</pub-id><pub-id pub-id-type="pmid">19955394</pub-id></citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figures and Tables</title>
<fig id="f1-ijms-11-02715" position="float">
<label>Figure 1.</label>
<caption>
<p>GST-pi immunostaining in human laryngeal tumors. (<bold>A</bold>) Patient 10, who had failed prior surgical treatment without radiation therapy; (<bold>B</bold>) Patient 5, who had failed prior treatment with radiation therapy; (<bold>C</bold>) Patient 7, who had failed previous treatment with radiation therapy. Positive immunohistochemical staining is brown. Images collected at 100× magnification.</p></caption><graphic xlink:href="ijms-11-02715f1.gif"/></fig>
<fig id="f2-ijms-11-02715" position="float">
<label>Figure 2.</label>
<caption>
<p>Immunohistochemical staining for (<bold>A</bold>) no primary antibody control; (<bold>B</bold>) eNOS, (<bold>C</bold>) iNOS, and (<bold>D</bold>) GST-pi in a single cervical sample. Positive immunohistochemical staining is brown. Strong staining is observed for iNOS and GST-pi, while little eNOS staining is apparent. Images collected at 250x magnification.</p></caption><graphic xlink:href="ijms-11-02715f2.gif"/></fig>
<fig id="f3-ijms-11-02715" position="float">
<label>Figure 3.</label>
<caption>
<p>Adaptation of A549 human lung adenocarcinoma cell line to high nitric oxide (HNO) levels. Adapted from reference [<xref ref-type="bibr" rid="b186-ijms-11-02715">186</xref>].</p></caption><graphic xlink:href="ijms-11-02715f3.gif"/></fig>
<fig id="f4-ijms-11-02715" position="float">
<label>Figure 4.</label>
<caption>
<p>Treatment of T-47D cell lines (Parent and HNO) to varying concentrations of H<sub>2</sub>O<sub>2</sub>. Adapted from reference [<xref ref-type="bibr" rid="b187-ijms-11-02715">187</xref>].</p></caption><graphic xlink:href="ijms-11-02715f4.gif"/></fig>
<fig id="f5-ijms-11-02715" position="float">
<label>Figure 5.</label>
<caption>
<p>Methylation of HHP1 and APC in parent and HNO MCF-7 cells.</p></caption><graphic xlink:href="ijms-11-02715f5.gif"/></fig>
<table-wrap id="t1-ijms-11-02715" position="float">
<label>Table 1.</label>
<caption>
<p>GST-pi immunohistochemical staining in human laryngeal tumors.</p></caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="center" valign="middle"><bold>Patient</bold></th>
<th align="center" valign="middle"><bold>Age/Sex</bold></th>
<th align="center" valign="middle"><bold>Tumor Location</bold></th>
<th align="center" valign="middle"><bold>Tumor Stage</bold></th>
<th align="center" valign="middle"><bold>Surgery Performed</bold></th>
<th align="center" valign="middle"><bold>Previous Treatment</bold></th>
<th align="center" valign="middle"><bold>GST-pi Intensity</bold></th>
<th align="center" valign="middle"><bold>GST-pi Pattern</bold></th></tr></thead>
<tbody>
<tr>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">74/M</td>
<td align="center" valign="middle">Larynx</td>
<td align="center" valign="middle">T3N0M0 (recurrent)</td>
<td align="left" valign="top">Total laryngectomy</td>
<td align="center" valign="middle">Chemo/XRT</td>
<td align="center" valign="middle">3+</td>
<td align="center" valign="middle">diffuse</td></tr>
<tr>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">79/F</td>
<td align="center" valign="middle">Pyriform sinus</td>
<td align="center" valign="middle">T3N0M0</td>
<td align="left" valign="top">Laryngopharyngectomy</td>
<td align="center" valign="middle">None</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">focal</td></tr>
<tr>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">73/M</td>
<td align="center" valign="middle">Subglottis</td>
<td align="center" valign="middle">T2N0M0</td>
<td align="left" valign="top">Total laryngectomy</td>
<td align="center" valign="middle">XRT</td>
<td align="center" valign="middle">3+</td>
<td align="center" valign="middle">diffuse</td></tr>
<tr>
<td align="center" valign="middle">4</td>
<td align="center" valign="middle">75/F</td>
<td align="center" valign="middle">Glottis</td>
<td align="center" valign="middle">T4N0M0</td>
<td align="left" valign="top">Laryngopharyngectomy</td>
<td align="center" valign="middle">None</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">diffuse</td></tr>
<tr>
<td align="center" valign="middle">5</td>
<td align="center" valign="middle">73/M</td>
<td align="center" valign="middle">Supraglottis</td>
<td align="center" valign="middle">T2N0M0 (recurrent)</td>
<td align="left" valign="top">Supraglottic laryngectomy</td>
<td align="center" valign="middle">XRT</td>
<td align="center" valign="middle">4+</td>
<td align="center" valign="middle">diffuse</td></tr>
<tr>
<td align="center" valign="middle">6</td>
<td align="center" valign="middle">63/M</td>
<td align="center" valign="middle">Supraglottis</td>
<td align="center" valign="middle">T4N2M0 (recurrent)</td>
<td align="left" valign="top">Completion laryngectomy</td>
<td align="center" valign="middle">Supraglottic laryngectomy, Chemo/XRT</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">diffuse</td></tr>
<tr>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">61/M</td>
<td align="center" valign="middle">Supraglottis</td>
<td align="center" valign="middle">T2N2M0 (recurrent)</td>
<td align="left" valign="top">Completion laryngectomy</td>
<td align="center" valign="middle">Supraglottic laryngectomy, Chemo/XRT</td>
<td align="center" valign="middle">4+</td>
<td align="center" valign="middle">diffuse</td></tr>
<tr>
<td align="center" valign="middle">8</td>
<td align="center" valign="middle">51/M</td>
<td align="center" valign="middle">Supraglottis</td>
<td align="center" valign="middle">T4N0M0 (recurrent)</td>
<td align="left" valign="top">Laryngopharyngectomy</td>
<td align="center" valign="middle">Chemo/XRT</td>
<td align="center" valign="middle">3+</td>
<td align="center" valign="middle">focal</td></tr>
<tr>
<td align="center" valign="middle">9</td>
<td align="center" valign="middle">77/M</td>
<td align="center" valign="middle">Larynx</td>
<td align="center" valign="middle">Recurrent</td>
<td align="left" valign="top">Total laryngectomy</td>
<td align="center" valign="middle">Chemo/XRT</td>
<td align="center" valign="middle">3+</td>
<td align="center" valign="middle">diffuse</td></tr>
<tr>
<td align="center" valign="middle">10</td>
<td align="center" valign="middle">81/M</td>
<td align="center" valign="middle">Larynx</td>
<td align="center" valign="middle">T3N0M0 (recurrent)</td>
<td align="left" valign="top">Completion laryngectomy</td>
<td align="center" valign="middle">Supraglottic laryngectomy</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">focal</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-ijms-11-02715">
<p>Chemo: chemotherapy, XRT: radiation therapy. Study was carried out with IRB approval.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="t2-ijms-11-02715" position="float">
<label>Table 2.</label>
<caption>
<p>Cervical cancer patient summary and immunohistochemistry data.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" valign="middle"><bold>Patient</bold></th>
<th align="center" valign="middle"><bold>Age</bold></th>
<th align="center" valign="middle"><bold>Stage</bold></th>
<th align="center" valign="middle"><bold>Grade</bold></th>
<th align="center" valign="middle"><bold>Treatment</bold></th>
<th align="center" valign="middle"><bold>Recurrence/Persistence</bold></th>
<th align="center" valign="middle"><bold>DFS (mos.)</bold></th>
<th align="center" valign="middle"><bold>iNOS Intensity</bold></th>
<th align="center" valign="middle"><bold>eNOS Intensity</bold></th>
<th align="center" valign="middle"><bold>GST-pi Intensity</bold></th></tr></thead>
<tbody>
<tr>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">39</td>
<td align="center" valign="middle">IIB</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">N</td>
<td align="center" valign="middle">32.5</td>
<td align="center" valign="middle">3+</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">1+</td></tr>
<tr>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">48</td>
<td align="center" valign="middle">IV</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">1+</td></tr>
<tr>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">65</td>
<td align="center" valign="middle">IIIB</td>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">Y</td>
<td align="center" valign="middle">12.5</td>
<td align="center" valign="middle">3+</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">0</td></tr>
<tr>
<td align="center" valign="middle">4</td>
<td align="center" valign="middle">41</td>
<td align="center" valign="middle">IIIB</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">Y</td>
<td align="center" valign="middle">4</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">1+</td></tr>
<tr>
<td align="center" valign="middle">5</td>
<td align="center" valign="middle">39</td>
<td align="center" valign="middle">IIIB</td>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">2+</td></tr>
<tr>
<td align="center" valign="middle">6</td>
<td align="center" valign="middle">50</td>
<td align="center" valign="middle">IB2</td>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">N</td>
<td align="center" valign="middle">37</td>
<td align="center" valign="middle">3+</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">2+</td></tr>
<tr>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">38</td>
<td align="center" valign="middle">IB1</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">S</td>
<td align="center" valign="middle">N</td>
<td align="center" valign="middle">39</td>
<td align="center" valign="middle">3+</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">1+</td></tr>
<tr>
<td align="center" valign="middle">8</td>
<td align="center" valign="middle">49</td>
<td align="center" valign="middle">IB2</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">N</td>
<td align="center" valign="middle">38</td>
<td align="center" valign="middle">3+</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">2+</td></tr>
<tr>
<td align="center" valign="middle">9</td>
<td align="center" valign="middle">63</td>
<td align="center" valign="middle">IIIB</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">Y</td>
<td align="center" valign="middle">9</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">1+</td></tr>
<tr>
<td align="center" valign="middle">10</td>
<td align="center" valign="middle">29</td>
<td align="center" valign="middle">IIB</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">R</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">1+</td></tr>
<tr>
<td align="center" valign="middle">11</td>
<td align="center" valign="middle">49</td>
<td align="center" valign="middle">IIIB</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">Y</td>
<td align="center" valign="middle">8</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">1+</td></tr>
<tr>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">49</td>
<td align="center" valign="middle">IIB</td>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">2+</td></tr>
<tr>
<td align="center" valign="middle">13</td>
<td align="center" valign="middle">61</td>
<td align="center" valign="middle">IIIB</td>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">2+</td></tr>
<tr>
<td align="center" valign="middle">14</td>
<td align="center" valign="middle">63</td>
<td align="center" valign="middle">IIB</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">N</td>
<td align="center" valign="middle">40</td>
<td align="center" valign="middle">3+</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">2+</td></tr>
<tr>
<td align="center" valign="middle">15</td>
<td align="center" valign="middle">44</td>
<td align="center" valign="middle">IIB</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">N</td>
<td align="center" valign="middle">42</td>
<td align="center" valign="middle">3+</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">2+</td></tr>
<tr>
<td align="center" valign="middle">16</td>
<td align="center" valign="middle">44</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">1+</td></tr>
<tr>
<td align="center" valign="middle">17</td>
<td align="center" valign="middle">52</td>
<td align="center" valign="middle">IVA</td>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">3+</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">2+</td></tr>
<tr>
<td align="center" valign="middle">18</td>
<td align="center" valign="middle">39</td>
<td align="center" valign="middle">IIB</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">N</td>
<td align="center" valign="middle">39</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">2+</td></tr>
<tr>
<td align="center" valign="middle">19</td>
<td align="center" valign="middle">51</td>
<td align="center" valign="middle">IIIB</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">N/A</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">1+</td></tr>
<tr>
<td align="center" valign="middle">20</td>
<td align="center" valign="middle">37</td>
<td align="center" valign="middle">IB1</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">S-R</td>
<td align="center" valign="middle">N</td>
<td align="center" valign="middle">35</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">1+</td></tr>
<tr>
<td align="center" valign="middle">21</td>
<td align="center" valign="middle">54</td>
<td align="center" valign="middle">IB2</td>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">N</td>
<td align="center" valign="middle">50</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">1+</td></tr>
<tr>
<td align="center" valign="middle">22</td>
<td align="center" valign="middle">49</td>
<td align="center" valign="middle">IIA</td>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">R</td>
<td align="center" valign="middle">N</td>
<td align="center" valign="middle">49</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">1+</td>
<td align="center" valign="middle">1+</td></tr>
<tr>
<td align="center" valign="middle">23</td>
<td align="center" valign="middle">48</td>
<td align="center" valign="middle">IIB</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">C-R</td>
<td align="center" valign="middle">N</td>
<td align="center" valign="middle">48</td>
<td align="center" valign="middle">2+</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">2+</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn2-ijms-11-02715">
<p>Staging by AJCC 2002 criteria. Treatment methods, C: chemotherapy, R: radiation therapy, S: surgery. DFS: Disease free survival. iNOS: inducible nitric oxide synthase; eNOS: endothelial constitutive nitric oxide synthase; GST-pi: glutathione S-transferase pi. Study was carried out with IRB approval.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="t3-ijms-11-02715" position="float">
<label>Table 3.</label>
<caption>
<p>The epigenetic impact of dysregulated DNA methylation on gene expression and human cancers.</p></caption>
<table frame="hsides" rules="rows">
<thead>
<tr>
<th align="left" valign="top"><bold>Gene</bold></th>
<th align="left" valign="top"><bold>Role/Function</bold></th>
<th align="left" valign="top"><bold>Tumor Type/Location</bold></th>
<th align="left" valign="top"><bold>Impact</bold></th>
<th align="left" valign="top"><bold>Reference(s)</bold></th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">APC</td>
<td align="left" valign="top">Inhibitor of β-catenin</td>
<td align="left" valign="top">Aerodigestive tract, lung, breast</td>
<td align="left" valign="top">Activation β –catenin route</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b107-ijms-11-02715">107</xref>–<xref ref-type="bibr" rid="b109-ijms-11-02715">109</xref>]</td></tr>
<tr>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">Androgen receptor</td>
<td align="left" valign="top">Prostate</td>
<td align="left" valign="top">Hormone insensitivity</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">BRCA1</td>
<td align="left" valign="top">DNA repair, transcription</td>
<td align="left" valign="top">Breast, ovarian</td>
<td align="left" valign="top">Double strand breaks</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b110-ijms-11-02715">110</xref>,<xref ref-type="bibr" rid="b111-ijms-11-02715">111</xref>]</td></tr>
<tr>
<td align="left" valign="top">CDH1</td>
<td align="left" valign="top">E cadherin, cell adhesion</td>
<td align="left" valign="top">Breast, stomach, Leukemia</td>
<td align="left" valign="top">Dissemination</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">CDH13</td>
<td align="left" valign="top">H cadherin, cell division</td>
<td align="left" valign="top">Breast, lung</td>
<td align="left" valign="top">Dissemination</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">CDKN2A/p16</td>
<td align="left" valign="top">Cyclin-dependent kinase inhibitor</td>
<td align="left" valign="top">Head, neck, gastrointestinal tract, lung, NHL</td>
<td align="left" valign="top">Entrance in cell cycle</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b78-ijms-11-02715">78</xref>,<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b108-ijms-11-02715">108</xref>,<xref ref-type="bibr" rid="b112-ijms-11-02715">112</xref>,<xref ref-type="bibr" rid="b113-ijms-11-02715">113</xref>]</td></tr>
<tr>
<td align="left" valign="top">COX2</td>
<td align="left" valign="top">Cycloxyenase-2</td>
<td align="left" valign="top">Colon, stomach</td>
<td align="left" valign="top">Anti-inflammatory resistance<sup>1</sup></td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">CPBP1</td>
<td align="left" valign="top">Retinol-binding protein</td>
<td align="left" valign="top">Colon, stomach, lymphoma</td>
<td align="left" valign="top">Vitamin insensitivity</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">DAPK1</td>
<td align="left" valign="top">Pro-apoptotic</td>
<td align="left" valign="top">Lymphoma, lung, colon</td>
<td align="left" valign="top">Resistance to apoptosis</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b108-ijms-11-02715">108</xref>]</td></tr>
<tr>
<td align="left" valign="top">DKK1</td>
<td align="left" valign="top">Extracellular Wnt inhibitor</td>
<td align="left" valign="top">Colon</td>
<td align="left" valign="top">Activation Wnt signaling</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">DNMT1</td>
<td align="left" valign="top">DNA disruption</td>
<td align="left" valign="top">Various</td>
<td align="left" valign="top">Over-expression</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">DNMT3b</td>
<td align="left" valign="top">DNA disruption</td>
<td align="left" valign="top">Various</td>
<td align="left" valign="top">Over-expression</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">E-cadherin</td>
<td align="left" valign="top">Increasing proliferation, invasion and/or metastasis</td>
<td align="left" valign="top">Breast, Thyroid, Gastric</td><td align="left" valign="top"/>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b114-ijms-11-02715">114</xref>–<xref ref-type="bibr" rid="b116-ijms-11-02715">116</xref>]</td></tr>
<tr>
<td align="left" valign="top">ER</td>
<td align="left" valign="top">Oestrogen receptor</td>
<td align="left" valign="top">Breast, prostate</td>
<td align="left" valign="top">Hormone insensitivity</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b117-ijms-11-02715">117</xref>,<xref ref-type="bibr" rid="b118-ijms-11-02715">118</xref>]</td></tr>
<tr>
<td align="left" valign="top">EXT1</td>
<td align="left" valign="top">Heparan intermediate filament</td>
<td align="left" valign="top">Leukemia, skin</td>
<td align="left" valign="top">Cellular detachment</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">FAT</td>
<td align="left" valign="top">Cadherin, tumor suppressor</td>
<td align="left" valign="top">Colon</td>
<td align="left" valign="top">Dissemination</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">GATA4</td>
<td align="left" valign="top">Transcription factor</td>
<td align="left" valign="top">Colon, stomach</td>
<td align="left" valign="top">Silencing of target genes</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">GATA5</td>
<td align="left" valign="top">Transcription factor</td>
<td align="left" valign="top">Colon, stomach</td>
<td align="left" valign="top">Silencing of target genes</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">GSTP1</td>
<td align="left" valign="top">Conjugation to glutathione</td>
<td align="left" valign="top">Prostate, breast, kidney</td>
<td align="left" valign="top">Adduct accumulation</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b108-ijms-11-02715">108</xref>,<xref ref-type="bibr" rid="b119-ijms-11-02715">119</xref>]</td></tr>
<tr>
<td align="left" valign="top">HIC1</td>
<td align="left" valign="top">Transcription factor</td>
<td align="left" valign="top">Various forms</td>
<td align="left" valign="top">Currently unknown</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">HOXA9</td>
<td align="left" valign="top">Homeobox protein</td>
<td align="left" valign="top">Neuroblastoma</td>
<td align="left" valign="top">Currently unknown</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">hMLH1</td>
<td align="left" valign="top">Defective DNA mismatch repair, gene mutations</td>
<td align="left" valign="top">Colon, Renal, Gastric, Endometrim, Ovarian</td><td align="left" valign="top"/>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b116-ijms-11-02715">116</xref>,<xref ref-type="bibr" rid="b120-ijms-11-02715">120</xref>–<xref ref-type="bibr" rid="b122-ijms-11-02715">122</xref>]</td></tr>
<tr>
<td align="left" valign="top">ID4</td>
<td align="left" valign="top">Transcription factor</td>
<td align="left" valign="top">Leukemia, stomach</td>
<td align="left" valign="top">Currently unknown</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">IGFBP3</td>
<td align="left" valign="top">Growth factor binding protein</td>
<td align="left" valign="top">Lung, skin</td>
<td align="left" valign="top">Resistance to apoptosis</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">Lamin A/C</td>
<td align="left" valign="top">Nuclear intermediate filament</td>
<td align="left" valign="top">Lymphoma, leukemia</td>
<td align="left" valign="top">Currently unknown</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">LKB1/STK11</td>
<td align="left" valign="top">Serine-theronine kinase</td>
<td align="left" valign="top">Colon, breast, lung</td>
<td align="left" valign="top">Currently unknown</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">MBD1</td>
<td align="left" valign="top">Rare mutations</td>
<td align="left" valign="top">Various</td>
<td align="left" valign="top">Over-expression</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">MBD2</td>
<td align="left" valign="top">Rare mutations</td>
<td align="left" valign="top">Various</td>
<td align="left" valign="top">Over-expression</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">MBD3</td>
<td align="left" valign="top">Rare mutations</td>
<td align="left" valign="top">Various</td>
<td align="left" valign="top">Over-expression</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">MBD4</td>
<td align="left" valign="top">Rare mutations</td>
<td align="left" valign="top">Various</td>
<td align="left" valign="top">Over-expression</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">MeCP2</td>
<td align="left" valign="top">Rare mutations</td>
<td align="left" valign="top">Various</td>
<td align="left" valign="top">Over-expression</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">MGMT</td>
<td align="left" valign="top">DNA repair of 06-alkyl-guanine, p53</td>
<td align="left" valign="top">Lung, brain, various</td>
<td align="left" valign="top">Mutations, chemosensitivity</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b123-ijms-11-02715">123</xref>,<xref ref-type="bibr" rid="b124-ijms-11-02715">124</xref>]</td></tr>
<tr>
<td align="left" valign="top">MLH1</td>
<td align="left" valign="top">DNA mismatch repair</td>
<td align="left" valign="top">Colon, endometrium, stomach, ovarian</td>
<td align="left" valign="top">Frameshift mutations, gene mutations</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">NORE1A</td>
<td align="left" valign="top">Ras effector homologue</td>
<td align="left" valign="top">Lung</td>
<td align="left" valign="top">Currently unknown</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">p14<sup>ARF</sup></td>
<td align="left" valign="top">MDM2 inhibitor</td>
<td align="left" valign="top">Colon, stomach. kidney</td>
<td align="left" valign="top">Degradation of p53</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">p15</td><td align="left" valign="top"/>
<td align="left" valign="top">Leukemia, Lymphoma</td>
<td align="left" valign="top">Entrance in cell cycle</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b125-ijms-11-02715">125</xref>–<xref ref-type="bibr" rid="b127-ijms-11-02715">127</xref>]</td></tr>
<tr>
<td align="left" valign="top">p15<sup>INK4b</sup></td>
<td align="left" valign="top">Cyclin-dependent kinase inhibitor</td>
<td align="left" valign="top">Leukemia, lymphoma, lung, SCC</td>
<td align="left" valign="top">Entrance in cell cycle</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">p16<sup>INK4a</sup></td>
<td align="left" valign="top">Cyclin-dependent kinase inhibitor</td>
<td align="left" valign="top">Various</td>
<td align="left" valign="top">Entrance in cell cycle</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b108-ijms-11-02715">108</xref>]</td></tr>
<tr>
<td align="left" valign="top">p73</td>
<td align="left" valign="top">P53 homologue</td>
<td align="left" valign="top">Lymphoma</td>
<td align="left" valign="top">Currently unknown</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">PR</td>
<td align="left" valign="top">Progestrogen receptor</td>
<td align="left" valign="top">Breast</td>
<td align="left" valign="top">Hormone insensitivity</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">PRLR</td>
<td align="left" valign="top">Prolactin receptor</td>
<td align="left" valign="top">Breast</td>
<td align="left" valign="top">Hormone insensitivity</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">RARβ2</td>
<td align="left" valign="top">Retinoic acid receptor –β2</td>
<td align="left" valign="top">Colon, lung, head and neck</td>
<td align="left" valign="top">Vitamin insensitivity</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">RASSF1A</td>
<td align="left" valign="top">Ras effector homologue</td>
<td align="left" valign="top">Lung, breast, ovarian, kidney, nasopharyngeal</td>
<td align="left" valign="top">Currently unknown</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b128-ijms-11-02715">128</xref>–<xref ref-type="bibr" rid="b130-ijms-11-02715">130</xref>]</td></tr>
<tr>
<td align="left" valign="top">Rb</td>
<td align="left" valign="top">Cell-cycle inhibitor</td>
<td align="left" valign="top">Retinoblastoma, oligodenodroglioma</td>
<td align="left" valign="top">Entrance to cell</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b131-ijms-11-02715">131</xref>,<xref ref-type="bibr" rid="b132-ijms-11-02715">132</xref>]</td></tr>
<tr>
<td align="left" valign="top">RIZ1</td>
<td align="left" valign="top">Histone/protein methyltransferase</td>
<td align="left" valign="top">Breast, liver</td>
<td align="left" valign="top">Abnormal gene expression</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">SFRP1</td>
<td align="left" valign="top">Secreted frizzled-related protein 1</td>
<td align="left" valign="top">Colon</td>
<td align="left" valign="top">Activation Wnt signaling</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">SLC5A8</td>
<td align="left" valign="top">Sodium transporter</td>
<td align="left" valign="top">Glioma, colon</td>
<td align="left" valign="top">Currently unknown</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">SOC1</td>
<td align="left" valign="top">Inhibitor of JAK-STAT pathway</td>
<td align="left" valign="top">Liver, mieloma</td>
<td align="left" valign="top">JAK2 activation</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">SOC3</td>
<td align="left" valign="top">Inhibitor of JAK-STAT pathway</td>
<td align="left" valign="top">Lung</td>
<td align="left" valign="top">JAK2 activation</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">SRBC</td>
<td align="left" valign="top">BRCA1-binding protein</td>
<td align="left" valign="top">Breast, lung</td>
<td align="left" valign="top">Currently unknown</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">SYK</td>
<td align="left" valign="top">Tyrosine kinase</td>
<td align="left" valign="top">Breast</td>
<td align="left" valign="top">Currently unknown</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">THBS1</td>
<td align="left" valign="top">Thrombospondin-1, anti-angiogenic</td>
<td align="left" valign="top">Giloma</td>
<td align="left" valign="top">Neo-vascularization</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">TMS1</td>
<td align="left" valign="top">Pro-apoptotic</td>
<td align="left" valign="top">Breast</td>
<td align="left" valign="top">Resistance to apoptosis</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">TPEF/HPP1</td>
<td align="left" valign="top">Transmembrane protein</td>
<td align="left" valign="top">Colon, bladder</td>
<td align="left" valign="top">Currently unknown</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">TSHR</td>
<td align="left" valign="top">Thyroid-stimulating hormone receptor</td>
<td align="left" valign="top">Thyroid</td>
<td align="left" valign="top">Hormone insensitivity</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">VHL</td>
<td align="left" valign="top">Ubiquitin ligase component</td>
<td align="left" valign="top">Kidney, haemangioblastoma</td>
<td align="left" valign="top">Loss of hypoxic response</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b129-ijms-11-02715">129</xref>]</td></tr>
<tr>
<td align="left" valign="top">WIF1</td>
<td align="left" valign="top">Wnt inhibitor factor</td>
<td align="left" valign="top">Colon, lung</td>
<td align="left" valign="top">Activation Wnt signaling</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr>
<tr>
<td align="left" valign="top">WRN</td>
<td align="left" valign="top">DNA repair</td>
<td align="left" valign="top">Colon, stomach, sarcoma</td>
<td align="left" valign="top">DNA breakage, chemosensitivity</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>]</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn3-ijms-11-02715">
<p>Abbreviations: NHL= Non-Hodgkin’s lymphoma, SCC= Squamous Cell Carcinoma, hMLH1= mutant homologue 1.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="t4-ijms-11-02715" position="float">
<label>Table 4.</label>
<caption>
<p>The epigenetic impact of NO<sup>•</sup>.</p></caption>
<table frame="hsides" rules="rows">
<thead>
<tr>
<th align="center" valign="middle"><bold>Substrate</bold></th>
<th align="center" valign="middle"><bold>Modification</bold></th>
<th align="center" valign="middle"><bold>Effect on Nucleosome/Chromatin</bold></th>
<th align="center" valign="middle"><bold>Transcription</bold></th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">AP-1</td>
<td align="center" valign="top">S-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">AtMYB2</td>
<td align="center" valign="top">S-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">Class II HDACs</td>
<td align="center" valign="top">Dephosphorylation</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">_</td></tr>
<tr>
<td align="left" valign="top">c-Myb</td>
<td align="center" valign="top">S-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">GR</td>
<td align="center" valign="top">T-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">+</td></tr>
<tr>
<td align="left" valign="top">HDAC2</td>
<td align="center" valign="top">S-N, T-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">+</td></tr>
<tr>
<td align="left" valign="top">HIF-1α</td>
<td align="center" valign="top">S-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">+</td></tr>
<tr>
<td align="left" valign="top">Histones</td>
<td align="center" valign="top">T-N</td>
<td align="center" valign="top">Direct</td>
<td align="center" valign="top">?</td></tr>
<tr>
<td align="left" valign="top">ikBα</td>
<td align="center" valign="top">T-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">+</td></tr>
<tr>
<td align="left" valign="top">NF-kB</td>
<td align="center" valign="top">S-N, T-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">Notch</td>
<td align="center" valign="top">T-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">Nuclear receptors</td>
<td align="center" valign="top">S-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">OxyR and SoxR</td>
<td align="center" valign="top">S-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">+</td></tr>
<tr>
<td align="left" valign="top">P53</td>
<td align="center" valign="top">T-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">PPARγ</td>
<td align="center" valign="top">T-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">-</td></tr>
<tr>
<td align="left" valign="top">β –catenin</td>
<td align="center" valign="top">T-N</td>
<td align="center" valign="top">Indirect</td>
<td align="center" valign="top">-</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn4-ijms-11-02715">
<p>Abbreviations: S-N= S-Nitrosylation, T-N= Tyr-Nitration. Adapted from reference [<xref ref-type="bibr" rid="b5-ijms-11-02715">5</xref>].</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="t5-ijms-11-02715" position="float">
<label>Table 5.</label>
<caption>
<p>The epigenetic impact of histone modification on gene expression and human cancers.</p></caption>
<table frame="hsides" rules="rows">
<thead>
<tr>
<th align="center" valign="middle"><bold>Gene</bold></th>
<th align="center" valign="middle"><bold>Tumor Type/Location</bold></th>
<th align="center" valign="middle"><bold>Impact</bold></th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">CBP<xref ref-type="table-fn" rid="tfn6-ijms-11-02715">1</xref></td>
<td align="left" valign="top">Colon, stomach, endometrium, lung, leukemia</td>
<td align="left" valign="top">Mutations, translocations, deletions</td></tr>
<tr>
<td align="left" valign="top">EZH2<xref ref-type="table-fn" rid="tfn8-ijms-11-02715">3</xref></td>
<td align="left" valign="top">Various types</td>
<td align="left" valign="top">Gene amplification, over-expression</td></tr>
<tr>
<td align="left" valign="top">GASC1<xref ref-type="table-fn" rid="tfn9-ijms-11-02715">4</xref></td>
<td align="left" valign="top">Squamous cell carcinoma</td>
<td align="left" valign="top">Gene amplification</td></tr>
<tr>
<td align="left" valign="top">HDAC1<xref ref-type="table-fn" rid="tfn7-ijms-11-02715">2</xref></td>
<td align="left" valign="top">Various types</td>
<td align="left" valign="top">Aberrant expression</td></tr>
<tr>
<td align="left" valign="top">HDAC2<xref ref-type="table-fn" rid="tfn7-ijms-11-02715">2</xref></td>
<td align="left" valign="top">Various types</td>
<td align="left" valign="top">Aberrant expression, mutations in MSI+</td></tr>
<tr>
<td align="left" valign="top">MLL1<xref ref-type="table-fn" rid="tfn8-ijms-11-02715">3</xref></td>
<td align="left" valign="top">Haematological malignancies</td>
<td align="left" valign="top">Translocation</td></tr>
<tr>
<td align="left" valign="top">MLL2<xref ref-type="table-fn" rid="tfn8-ijms-11-02715">3</xref></td>
<td align="left" valign="top">Glioma, pancreas</td>
<td align="left" valign="top">Gene amplification</td></tr>
<tr>
<td align="left" valign="top">MLL3<xref ref-type="table-fn" rid="tfn8-ijms-11-02715">3</xref></td>
<td align="left" valign="top">Leukemia</td>
<td align="left" valign="top">Deletion</td></tr>
<tr>
<td align="left" valign="top">MORF<xref ref-type="table-fn" rid="tfn6-ijms-11-02715">1</xref></td>
<td align="left" valign="top">Haematological malignancies, leiomyomata</td>
<td align="left" valign="top">Translocations</td></tr>
<tr>
<td align="left" valign="top">MOZ<xref ref-type="table-fn" rid="tfn6-ijms-11-02715">1</xref></td>
<td align="left" valign="top">Haematological malignancies</td>
<td align="left" valign="top">Translocations</td></tr>
<tr>
<td align="left" valign="top">NSD1<xref ref-type="table-fn" rid="tfn8-ijms-11-02715">3</xref></td>
<td align="left" valign="top">Leukemia</td>
<td align="left" valign="top">Translocation</td></tr>
<tr>
<td align="left" valign="top">p300<xref ref-type="table-fn" rid="tfn6-ijms-11-02715">1</xref></td>
<td align="left" valign="top">Colon, stomach, endometrium</td>
<td align="left" valign="top">Mutations in MSI+</td></tr>
<tr>
<td align="left" valign="top">pCAF<xref ref-type="table-fn" rid="tfn6-ijms-11-02715">1</xref></td>
<td align="left" valign="top">Colon</td>
<td align="left" valign="top">Rare mutations</td></tr>
<tr>
<td align="left" valign="top">RIZ1<xref ref-type="table-fn" rid="tfn8-ijms-11-02715">3</xref></td>
<td align="left" valign="top">Various types</td>
<td align="left" valign="top">CpG-island hypermethylation</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn5-ijms-11-02715">
<p>Abbreviations: MSI+= Microsatellite instable tumors. Footnotes:</p></fn><fn id="tfn6-ijms-11-02715">
<label>1</label>
<p>Histone acetyltransferases,</p></fn><fn id="tfn7-ijms-11-02715">
<label>2</label>
<p>Histone deactylases,</p></fn><fn id="tfn8-ijms-11-02715">
<label>3</label>
<p>Histone methyltransferases,</p></fn><fn id="tfn9-ijms-11-02715">
<label>4</label>
<p>Histone demethylase. Adapted from references [<xref ref-type="bibr" rid="b90-ijms-11-02715">90</xref>,<xref ref-type="bibr" rid="b107-ijms-11-02715">107</xref>,<xref ref-type="bibr" rid="b109-ijms-11-02715">109</xref>].</p></fn></table-wrap-foot></table-wrap></sec></back></article>
